Cancer Research and Treatment

Original Articles

Malignant Hepatocellular Neoplasm, not Otherwise Specified, Displays Poorer Chemoresponsiveness and Postoperative Prognosis than Hepatoblastoma: In Hye Song, Sujin Gang, Hee Mang Yoon, Pyeong Hwa Kim, Bokyung Ahn, Jihun Kim, Deok Hoon Kim, Jung-Man Namgoong, Kyung-Nam Koh; Received February 1, 2025 Accepted April 27, 2025 Published online May 12, 2025; DOI: https://doi.org/10.4143/crt.2025.117 [Accepted]

Abstract PDF Supplementary Material: Purpose
Malignant hepatocellular neoplasm, not otherwise specified (HCN-NOS) is a provisional diagnostic entity, characterised by intermediate or a combination of hepatoblastoma and paediatric hepatocellular carcinoma (p-HCC) features. We compared the characteristics of HCN-NOS with hepatoblastoma and p-HCC.
Materials and Methods
The records of 148 paediatric patients diagnosed with hepatocellular malignancy after resection were retrieved from the institutional database. Clinical parameters and histopathology slides were reviewed to re-establish each patient’s diagnosis. Molecular analyses were conducted in 37 patients.
Results
Patients were profiled as 21 (14.2%) with HCN-NOS, 109 (73.6%) with hepatoblastoma, and 18 (12.2%) with p-HCC. The median age was 8.6 years in HCN-NOS, 1.2 years in hepatoblastoma, and 7.9 years in p-HCC. Background liver disease was frequently observed in p-HCC (11/18, 61%) but infrequent in HCN-NOS (4/21, 19%) and hepatoblastoma (4/109, 3.7%). HCN-NOS presented with a more advanced PRETEXT stage (p=0.012), metastasis (p<0.001), and lymphovascular invasion (p<0.001) than hepatoblastoma and p-HCC. Patients with HCN-NOS received longer cycles of preoperative chemotherapy; however, they reported a lower decrease in serum alpha-fetoprotein and tumour size than hepatoblastoma (p=0.043, 0.004, 0.044, respectively). HCN-NOS was an independent poor prognostic factor for event-free survival (hazard ratio, 4.968; 95% confidence interval, 2.004–12.32; p<0.001).
Conclusion
The possibility of HCN-NOS should be considered in paediatric patients with liver cancer, especially those ≥ 5 years old with no background liver disease. Because HCN-NOS exhibits poor chemo-responsiveness and unfavourable postoperative prognosis, liver transplantation should be strongly considered.

186 View
19 Download

Evaluation of Nomenclature of Fatty Liver Disease in Association with Hepatocellular Carcinoma: A 14.5-Year Cohort Study in Korea: Tung Hoang, Jeonghee Lee, Bo Hyun Kim, Yuri Cho, Jeongseon Kim; Received September 7, 2024 Accepted February 10, 2025 Published online February 11, 2025; DOI: https://doi.org/10.4143/crt.2024.876 [Accepted]

Purpose
New nomenclature has incorporated metabolic traits and/or alcohol intake history to replace nonalcoholic fatty liver disease (NAFLD). Concerning the performance of different terminologies in Asian population, this study aimed to investigate the risk of developing hepatocellular carcinoma (HCC) in persons meeting the criteria for subclasses of fatty liver disease.
Materials and Methods
Between 2002 and 2021, 28,749 participants from the cancer registry linkage, who had no prior history of HCC, were prospectively included. Fatty liver disease was defined using abdominal sonography and fatty liver index. Participants were classified as having NAFLD, metabolic dysfunction–associated fatty liver disease (MAFLD), metabolic dysfunction-associated steatotic liver disease (MASLD), steatotic liver disease with increased alcohol intake (MetALD), or alcohol-related liver disease (ALD) and their association with HCC risk was investigated using Cox regression models.
Results
During a median follow-up of 14.5 years, 166 HCC cases were newly diagnosed. The prevalences of NAFLD and MASLD were 19.7% and 18.7%, respectively, whereas MAFLD was observed in 35.2% of the study population. Given the low proportion of excessive alcohol consumption, we identified 3.3% MetALD and 3.5% ALD cases. Overall, MAFLD was suggestively associated with HCC risk (hazard ratio, 1.40; 95% confidence interval 0.99-1.98). In contrast, the results for other nomenclature were not significant.
Conclusion
Our results suggest the importance of both fatty liver and the presence of metabolic dysfunction in relation to HCC risk and the need to reconsider alcohol intake thresholds in the diagnostic criteria for NAFLD and MASLD within the Korean population.

Citations

Citations to this article as recorded by

Dual etiology vs. MetALD: how MAFLD and MASLD address liver diseases coexistence
Shadi Zerehpooshnesfchi, Amedeo Lonardo, Jian-Gao Fan, Reda Elwakil, Tawesak Tanwandee, Munira Y. Altarrah, Necati Örmeci, Mohammed Eslam
Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Comment on " posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program"
Junwei Guo, Dongsheng Huang
Journal of the Formosan Medical Association.2025;[Epub] CrossRef
MAFLD vs. MASLD: a year in review
Mingqian Jiang, Amna Subhan Butt, Ian Homer Cua, Ziyan Pan, Said A Al-Busafi, Nahum Méndez-Sánchez, Mohammed Eslam
Expert Review of Endocrinology & Metabolism.2025; : 1. CrossRef

812 View
61 Download
3 Crossref

Preoperative Prediction Model for Early Recurrence of Intrahepatic Cholangiocarcinoma After Surgical Resection: Development and External Validation Study: Dong Hwan Kim, Sang Hyun Choi, Sehee Kim, Hyungjin Rhee, Eun-Suk Cho, Suk-Keu Yeom, Sumi Park, Seung Soo Lee, Mi-Suk Park; Received December 10, 2024 Accepted February 4, 2025 Published online February 5, 2025; DOI: https://doi.org/10.4143/crt.2024.1187 [Accepted]

Abstract PDF: Purpose
We aimed to develop a preoperative risk scoring system to predict early recurrence (ER) of intrahepatic cholangiocarcinoma (ICCA) after resection, utilizing clinical and computed tomography (CT) features.
Materials and Methods
This multicenter study included 365 patients who underwent curative-intent surgical resection for ICCA at six institutions between 2009 and 2016. Of these, 264 patients from one institution constituted the development cohort, while 101 patients from the other institutions constituted the external validation cohort. Logistic regression models were constructed to predict ER based on preoperative variables and were subsequently translated into a risk-scoring system. The discrimination performance of the risk-scoring system was validated using external data and compared to the American Joint Committee on Cancer (AJCC) TNM staging system.
Results
Among the 365 patients (mean age, 62±10 years), 153 had ER. A preoperative risk scoring system that incorporated both clinical and CT features demonstrated superior discriminatory performance compared to the postoperative AJCC TNM staging system in both the development (area under the curve [AUC], 0.78 vs. 0.68; p=0.002) and validation cohorts (AUC, 0.69 vs. 0.66; p=0.641). The preoperative risk scoring system effectively stratified patients based on their risk for ER: the 1-year recurrence-free survival rates for the low, intermediate, and high-risk groups were 85.5%, 56.6%, and 15.6%, respectively (p<0.001) in the development cohort, and 87.5%, 58.5%, and 25.0%, respectively (p<0.001) in the validation cohort.
Conclusion
A preoperative risk scoring system that incorporates clinical and CT imaging features was valuable in identifying high-risk patients with ICCA for ER following resection.

480 View
52 Download

Special Article

Trends in Cancer-Screening Rates in Korea: Findings from the National Cancer Screening Survey, 2004-2023: EunKyo Kang, Kui Son Choi, Jae Kwan Jun, Yeol Kim, Hyeon Ji Lee, Chang Kyun Choi, Tae Hee Kim, Sun Hwa Lee, Mina Suh; Cancer Res Treat. 2025;57(1):28-38. Published online August 2, 2024; DOI: https://doi.org/10.4143/crt.2024.325

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to report the overall national trends in the rates of cancer screening based on recommendations and provide insights into the changing trends of these rates across different demographics.
Materials and Methods
This study used data from the Korean National Cancer Screening Survey (KNCSS), which surveys nationwide cancer-screening rates and includes 4,500 individuals meeting the Korean National Cancer Screening Program (NCSP) protocol age criteria. Cancer-screening rates were assessed using structured questionnaires; yearly trends were analyzed for both lifetime cancer-screening rates and rates of screening based on recommendations, and subgroup analyses were performed based on age and sex.
Results
The rates of cancer screening based on recommendations showed significant increments: the stomach cancer-screening rate increased from 39.2% in 2004 to 77.5% in 2023 (3.50% per year), the liver cancer-screening rate increased from 20.0% to 48.8% (4.30% per year), and the colorectal cancer, increased from 19.9% to 70.7% (5.15% per year). The breast cancer-screening rate increased from 33.2% to 72.7% (2.88% per year), and the cervical cancer, increased from 58.3% to 70.2% (1.08% per year). Despite some differences, particularly in relation to sociodemographic factors, screening rates increased significantly for all cancer types.
Conclusion
Cancer-screening rates in Korea increased consistently from 2004 to 2023, demonstrating the effectiveness of the national cancer-screening program. However, the increments in breast, cervical and lung cancer-screening rates were relatively lower, indicating the need for additional efforts and strategies.

Citations

Citations to this article as recorded by

Association Between Suicidal Ideation and Cancer Screening Uptake: Results from Middle-Aged and Older Adults in Korea
Seong-Uk Baek, Jin-Ha Yoon
Cancers.2025; 17(6): 956. CrossRef

2,904 View
186 Download
1 Web of Science
1 Crossref

Original Article

Gastrointestinal cancer

Clinical and Radiologic Predictors of Response to Atezolizumab-Bevacizumab in Advanced Hepatocellular Carcinoma: Se Jin Choi, Sung Won Chung, Jonggi Choi, Kang Mo Kim, Hyung-Don Kim, Changhoon Yoo, Baek-Yeol Ryoo, Seung Soo Lee, Won-Mook Choi, Sang Hyun Choi; Cancer Res Treat. 2024;56(4):1219-1230. Published online May 7, 2024; DOI: https://doi.org/10.4143/crt.2024.283

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to identify clinical and radiologic characteristics that could predict response to atezolizumab-bevacizumab combination therapy in patients with advanced hepatocellular carcinoma (HCC).
Materials and Methods
This single-center retrospective study included 108 advanced HCC patients with intrahepatic lesions who were treated with atezolizumab-bevacizumab. Two radiologists independently analyzed imaging characteristics of the index tumor on pretreatment computed tomography. Predictive factors associated with progressive disease (PD) at the best response based on Response Evaluation Criteria in Solid Tumors, ver. 1.1 were evaluated using logistic regression analysis. Progression-free survival (PFS) was estimated by the Kaplan-Meier method and compared with the log-rank test.
Results
Of 108 patients with a median PFS of 15 weeks, 40 (37.0%) had PD during treatment. Factors associated with PD included the presence of extrahepatic metastases (adjusted odds ratio [aOR], 4.13; 95% confidence interval [CI], 1.19 to 14.35; p=0.03), the infiltrative appearance of the tumor (aOR, 3.07; 95% CI, 1.05 to 8.93; p=0.04), and the absence of arterial-phase hyperenhancement (APHE) (aOR, 6.34; 95% CI, 2.18 to 18.47; p < 0.001). Patients with two or more of these factors had a PD of 66.7% and a median PFS of 8 weeks, indicating a significantly worse outcome compared to the patients with one or no of these factors.
Conclusion
In patients with advanced HCC treated with atezolizumab-bevacizumab treatment, the absence of APHE, infiltrative appearance of the intrahepatic tumor, and presence of extrahepatic metastases were associated with poor response and survival. Evaluation of early response may be necessary in patients with these factors.

Citations

Citations to this article as recorded by

Liver Transplantation for Hepatocarcinoma: Results over Two Decades of a Transplantation Programme and Analysis of Factors Associated with Recurrence
María Martínez Burgos, Rocío González Grande, Susana López Ortega, Inmaculada Santaella Leiva, Jesús de la Cruz Lombardo, Julio Santoyo Santoyo, Miguel Jiménez Pérez
Biomedicines.2024; 12(6): 1302. CrossRef

2,127 View
124 Download
1 Web of Science
1 Crossref

Review Article

Metastasis-Directed Local Therapy of Hepatic Oligometastasis from Colorectal Cancer and Future Perspective in Radiation Therapy: Gyu Sang Yoo, Chai Hong Rim, Won Kyung Cho, Jae-Uk Jeong, Eui Kyu Chie, Hyeon-Min Cho, Jun Won Um, Yong Chan Ahn, Jong Hoon Lee, on behalf of Korean Cancer Association Oligometastasis Working Group; Cancer Res Treat. 2023;55(3):707-719. Published online March 15, 2023; DOI: https://doi.org/10.4143/crt.2022.1599

Abstract PDF PubReader ePub

Introduction of the concept for oligometastasis led to wide application of metastasis-directed local ablative therapies for metastatic colorectal cancer (CRC). By application of the metastasis-directed local ablative therapies including surgical resection, radiofrequency ablation (RFA), and stereotactic ablative body radiotherapy (SABR), the survival outcomes of patients with metastatic CRC have improved. The liver is the most common distant metastatic site in CRC patients, and recently various metastasis-directed local therapies for hepatic oligometastasis from CRC (HOCRC) are widely used. Surgical resection is the first line of metastatic-directed local therapy for HOCRC, but its eligibility is very limited. Alternatively, RFA can be applied to patients who are ineligible for surgical resection of liver metastasis. However, there are some limitations such as inferior local control (LC) compared with surgical resection and technical feasibility based on location, size, and visibility on ultrasonography of the liver metastasis. Recent advances in radiation therapy technology have led to an increase in the use of SABR for liver tumors. SABR is considered complementary to RFA for patients with HOCRC who are ineligible for RFA. Furthermore, SABR can potentially result in better LC for liver metastases > 2-3 cm compared with RFA. In this article, the previous studies regarding curative metastasis-directed local therapies for HOCRC based on the radiation oncologist’s and surgeon’s perspective are reviewed and discussed. In addition, future perspectives regarding SABR in the treatment of HOCRC are suggested.

Citations

Citations to this article as recorded by

Identifying Trends in Oncology Research through a Bibliographic Analysis of Cancer Research and Treatment
Choong-kun Lee, Jeong Min Choo, Yong Chan Ahn, Jin Kim, Sun Young Rha, Chai Hong Rim
Cancer Research and Treatment.2025; 57(1): 11. CrossRef
Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 4: Liver and locally recurrent rectal cancer
Hwa Kyung Byun, Gyu Sang Yoo, Soo-Yoon Sung, Jin-Ho Song, Byoung Hyuck Kim, Yoo-Kang Kwak, Yeon Joo Kim, Yeon-Sil Kim, Kyung Su Kim
Radiation Oncology Journal.2024; 42(4): 247. CrossRef

5,580 View
298 Download
3 Web of Science
2 Crossref

Original Articles

Lung and Thoracic cancer

Clinical Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials: Qing Yin, Longguo Dai, Ruizhu Sun, Ping Ke, Liya Liu, Bo Jiang; Cancer Res Treat. 2022;54(3):803-816. Published online October 25, 2021; DOI: https://doi.org/10.4143/crt.2021.764

Abstract PDF Supplementary Material PubReader ePub

Purpose
This network meta-analysis (NMA) was conducted to compare the efficacy of immune checkpoint inhibitors in advanced non–small cell lung cancer (NSCLC) patients with liver metastases.
Materials and Methods
English literature was retrieved from the PubMed, American Society of Clinical Oncology, and European Society for Medical Oncology databases from January 2015 to January 2021. We pooled the overall survival (OS) and progression-free survival (PFS) hazard ratios (HRs) using an NMA and ranked treatments by the surface under the cumulative ranking curve. Publication bias was evaluated by Begg’s and Egger’s tests. STATA 15.0 was used for the sensitivity analysis, and the remaining statistical analyses were performed using R 4.0.2.
Results
Nine eligible phase III randomized controlled trials were included, including 1,141 patients with liver metastases. Pembrolizumab+chemotherapy ranked highest, followed by atezolizumab+bevacizumab+chemotherapy and nivolumab. However, no significant difference in OS rates was observed across these three treatments (HR, 0.98; 95% confidence interval [CI], 0.43 to 2.22 for pembrolizumab+chemotherapy vs. atezolizumab+bevacizumab+chemotherapy; HR, 0.91; 95% CI, 0.52 to 1.57 for pembrolizumab+chemotherapy vs. nivolumab). Regarding the PFS rate, atezolizumab+bevacizumab+chemotherapy and pembro-lizumab+chemotherapy ranked highest and no significant difference was observed between them (HR, 0.79; 95% CI, 0.36 to 1.70 for atezolizumab+bevacizumab+chemotherapy vs. pembrolizumab+chemotherapy).
Conclusion
Pembrolizumab+chemotherapy, atezolizumab+bevacizumab+chemotherapy, and nivolumab were superior to other treatments in NSCLC patients with liver metastases. These new findings may help clinicians better select therapeutic strategies for NSCLC patients with liver metastases.

Citations

Citations to this article as recorded by

The Mechanism of Lactic Acid Regulating Platelet-Derived Microparticles to Affect the Biological Characteristics of Human Lung Adenocarcinoma
红艳刘
Advances in Clinical Medicine.2025; 15(01): 274. CrossRef
Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases
Fan-jie Qu, Yi Zhou, Shuang Wu
British Journal of Cancer.2024; 130(2): 165. CrossRef
Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
Daisuke Hazama, Kenji Nakahama, Hiroaki Kodama, Akito Miyazaki, Koichi Azuma, Yosuke Kawashima, Yuki Sato, Kentaro Ito, Yoshimasa Shiraishi, Keita Miura, Takayuki Takahama, Satoshi Oizumi, Yoshinobu Namba, Satoshi Ikeda, Hiroshige Yoshioka, Asuka Tsuya, Y
JTO Clinical and Research Reports.2024; 5(1): 100613. CrossRef
Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer
Lingling Zhu, Xianzhe Yu, Xiaojun Tang, Chenggong Hu, Lei Wu, Yanyang Liu, Qinghua Zhou
Chinese Medical Journal.2024; 137(9): 1019. CrossRef
Treatment Options for Patients with Non-Small Cell Lung Cancer and Liver Metastases
Vesna Ćeriman Krstić, Natalija Samardžić, Milija Gajić, Milan Savić, Biljana Šeha, Marina Roksandić Milenković, Dragana Jovanović
Current Issues in Molecular Biology.2024; 46(12): 13443. CrossRef
Assessing the Relationship Between Liver Metastases and the Survival of Patients With Non-Small Cell Lung Cancer After Immune Checkpoint Inhibitors Treatment: A Systematic Review and Meta-Analysis
Huilin Xu, Pingpo Ming, Zhenyu Zhao, Nan Zhao, Dingjie Zhou, Xixian Tang, Dedong Cao
Integrative Cancer Therapies.2023;[Epub] CrossRef
Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis
Handai Xia, Wengang Zhang, Yuqing Zhang, Xiaoling Shang, Yanguo Liu, Xiuwen Wang
Frontiers in Oncology.2022;[Epub] CrossRef

8,158 View
259 Download
7 Web of Science
7 Crossref

Gastrointestinal cancer

Radiofrequency Ablation versus Stereotactic Body Radiation Therapy in the Treatment of Colorectal Cancer Liver Metastases: Jesang Yu, Dong Hwan Kim, Jungbok Lee, Yong Moon Shin, Jong Hoon Kim, Sang Min Yoon, Jinhong Jung, Jin Cheon Kim, Chang Sik Yu, Seok-Byung Lim, In Ja Park, Tae Won Kim, Yong Sang Hong, Sun Young Kim, Jeong Eun Kim, Jin-hong Park, So Yeon Kim; Cancer Res Treat. 2022;54(3):850-859. Published online October 13, 2021; DOI: https://doi.org/10.4143/crt.2021.674

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to compare the treatment outcomes of radiofrequency ablation (RFA) and stereotactic body radiation therapy (SBRT) for colorectal cancer liver metastases (CRLM) and to determine the favorable treatment modality according to tumor characteristics.
Materials and Methods
We retrospectively analyzed the records of 222 colorectal cancer patients with 330 CRLM who underwent RFA (268 tumors in 178 patients) or SBRT (62 tumors in 44 patients) between 2007 and 2014. Kaplan–Meier method and Cox models were used by adjusting with inverse probability of treatment weighting (IPTW).
Results
The median follow-up duration was 30.5 months. The median tumor size was significantly smaller in the RFA group than in the SBRT group (1.5 cm vs 2.3 cm, p<0.001). In IPTW-adjusted analysis, difference in treatment modality was not associated with significant differences in 1-year and 3-year recurrence-free survival (35% vs 43%, 22% vs 23%; p=0.198), overall survival (96% vs 91%, 58% vs 56%; p=0.508), and freedom from local progression (FFLP; 90% vs 72%, 78% vs 60%; p=0.106). Significant interaction effect between the treatment modality and tumor size was observed for FFLP (p=0.001). In IPTW-adjusted subgroup analysis of patients with tumor size >2 cm, the SBRT group had a higher FFLP compared with the RFA group (HR, 0.153; p<0.001).
Conclusion
SBRT and RFA showed similar local control in the treatment of patients with CRLM. Tumor size was an independent prognostic factor for local control and SBRT may be preferred for larger tumors.

Citations

Citations to this article as recorded by

Ablative techniques in colorectal liver metastases: A systematic review, descriptive summary of practice, and recommendations for optimal data reporting
Wee Han Ng, Catarina Machado, Alice Rooney, Robert Jones, Jonathan Rees, Samir Pathak
European Journal of Surgical Oncology.2025; 51(2): 109487. CrossRef
Effects of maximum dose on local control after stereotactic body radiotherapy for oligometastatic tumors of colorectal cancer
Su Jin Kang, Jongmoo Park, Gyu-Seog Choi, Jong Gwang Kim, Jun Seok Park, Hye Jin Kim, Jin Ho Baek, Byung Woog Kang, An Na Seo, Shin-Hyung Park, Bong Kyung Bae, Min Kyu Kang, Soo Yeun Park, Devarati Mitra
PLOS ONE.2025; 20(1): e0313438. CrossRef
Treatment of Oligometastatic GI Cancers
Clayton T. Marcinak, Patrick B. Schwartz, Mustafa M. Basree, Newton Hurst, Michael Bassetti, Jeremy D. Kratz, Nataliya V. Uboha
American Society of Clinical Oncology Educational Book.2024;[Epub] CrossRef
Stereotactic radiotherapy for liver oligometastases: a pooled analysis following the estro/eortc consensus recommendations
D. Pezzulla, G. Chiloiro, E. M. Lima, G. Macchia, C. Romano, S. Reina, G. Panza, S. Cilla, A. G. Morganti, F. Cellini, M. A. Gambacorta, F. Deodato
Clinical & Experimental Metastasis.2024; 41(5): 667. CrossRef
Interventionelle Therapieoptionen bei oligometastasierten Tumoren
Max Seidensticker
Forum.2024; 39(5): 340. CrossRef
Efficacy and safety of B-ultrasound-guided radiofrequency ablation in the treatment of primary liver cancer: Systematic review and meta-analysis
Xiong Zhang, Hong-Yi Zhu, Ming Yuan
World Journal of Gastrointestinal Surgery.2024; 16(9): 2986. CrossRef
Analysis of alkaline phosphatase and γ-glutamyltransferase after radiofrequency ablation of primary liver cancer: A retrospective study
Wen-Yu Huang, Sheng Zheng, Dan Zhu, Ying-Lang Zeng, Juan Yang, Xue-Li Zeng, Pei Liu, Shun-Ling Zhang, Ming Yuan, Zhi-Xia Wang
World Journal of Gastrointestinal Surgery.2024; 16(9): 2860. CrossRef
Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 4: Liver and locally recurrent rectal cancer
Hwa Kyung Byun, Gyu Sang Yoo, Soo-Yoon Sung, Jin-Ho Song, Byoung Hyuck Kim, Yoo-Kang Kwak, Yeon Joo Kim, Yeon-Sil Kim, Kyung Su Kim
Radiation Oncology Journal.2024; 42(4): 247. CrossRef
Recent trends in radiotherapy use for major cancers in Korea
Kyungmi Yang, Jeong Eun Lee, Won Park, Yong Chan Ahn, Seung Jae Huh
Japanese Journal of Clinical Oncology.2023; 53(12): 1177. CrossRef
Combination of endoscopic ultrasound-guided radiofrequency ablation and adaptive radiation therapy for the treatment of lymph node metastases from colon adenocarcinoma: A case report
Federica Borrelli de Andreis, Maria Alessandra Calegari, Angela Romano, Maria Gabriella Brizi, Luigi Sofo, Ivo Boskoski, Guido Costamagna, Fabia Attili
Current Problems in Cancer: Case Reports.2023; 9: 100216. CrossRef
Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis
Chai Hong Rim, Jung Sue Lee, Soo Yeon Kim, Jinsil Seong
JHEP Reports.2023; 5(1): 100594. CrossRef
Metastasis-Directed Local Therapy of Hepatic Oligometastasis from Colorectal Cancer and Future Perspective in Radiation Therapy
Gyu Sang Yoo, Chai Hong Rim, Won Kyung Cho, Jae-Uk Jeong, Eui Kyu Chie, Hyeon-Min Cho, Jun Won Um, Yong Chan Ahn, Jong Hoon Lee
Cancer Research and Treatment.2023; 55(3): 707. CrossRef
Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century
Sara Mheid, Stefan Allen, Sylvia S. W. Ng, William A. Hall, Nina N. Sanford, Todd A. Aguilera, Ahmed M. Elamir, Rana Bahij, Martijn P. W. Intven, Ganesh Radhakrishna, Issa Mohamad, Jeremy De Leon, Hendrick Tan, Shirley Lewis, Cihan Gani, Teo Stanecu, Vero
Current Oncology.2023; 30(10): 9230. CrossRef
Evidence on percutaneous radiofrequency and microwave ablation for liver metastases over the last decade
Koji Tomita, Yusuke Matsui, Mayu Uka, Noriyuki Umakoshi, Takahiro Kawabata, Kazuaki Munetomo, Shoma Nagata, Toshihiro Iguchi, Takao Hiraki
Japanese Journal of Radiology.2022; 40(10): 1035. CrossRef

9,494 View
299 Download
13 Web of Science
14 Crossref

Gastrointestinal Cancer

Fasting Blood Glucose, Cholesterol, and Risk of Primary Liver Cancer: The Kailuan Study: Xiangming Ma, Haozhe Cui, Miaomiao Sun, Qian Liu, Xining Liu, Guangjian Li, Yaochen Wei, Qingjiang Fu, Siqing Liu, Liying Cao; Cancer Res Treat. 2021;53(4):1113-1122. Published online January 19, 2021; DOI: https://doi.org/10.4143/crt.2020.817

Abstract PDF PubReader ePub

Purpose
The influence of fasting blood glucose (FBG) and cholesterolemia primary liver cancer (PLC) in china was analyzed via a large prospective cohort study based on a community population, and the combined effects between them were investigated.
Materials and Methods
Overall, 98,936 staff from the Kailuan Group who participated in and finished physical examinations between 2006 and 2007 were included in the cohort study. Their medical information was collected and they were followed up after examination. The correlations of serum FBG or TC with PLC were analyzed. Then, we categorized all staff into four groups: normal FBG/ non-hypocholesterolemia, normal FBG/hypocholesterolemia, elevated FBG/non-hypocholesterolemia, elevated FBG/hypocholesterolemia and normal FBG/ non-hypocholesterolemia was used as a control group. The combined effects of elevated FBG and hypocholesterolemia with PLC were analyzed using the Age-scale Cox proportional hazard regression model.
Results
During 1,134,843.68 person*years follow up, a total of 388 PLC cases occured. We found the elevated FBG and hypocholesterolemia increases the risk for PLC, respectively. Compared with the non-hypocholesterolemia/normal FBG group, the risk of PLC was significantly increased in the non-hypocholesterolemia/elevated FBG group (HR=1.19,95%CI 0.88–1.62) and hypocholesterolemia/normal FBG group (HR=1.53,95%CI 1.19–1.97), and in the hypocholesterolemia/elevated FBG group (HR=3.16 95%CI2.13-4.69). And, a significant interaction effect was found of FBG and TC on PLC. All results were independent from the influence of liver disease.
Conclusion
Elevated serum FBG and hypocholesterolemia are risk factors for PLC, especially when combined. Thus, for the prevention and treatment of PLC, serum FBG and TC levels should be investigated.

Citations

Citations to this article as recorded by

The role of glucose-6-phosphatase activity in glucose homeostasis and its potential for diabetes therapy
Lay Shuen Tan, Hwee Hui Lau, Essam M. Abdelalim, Chin Meng Khoo, Richard M. O’Brien, E. Shyong Tai, Adrian Kee Keong Teo
Trends in Molecular Medicine.2025; 31(2): 152. CrossRef
Causality of blood metabolites on hepatocellular carcinoma and cholangiocarcinoma: a metabolome-wide mendelian randomization study
Lin Ning, Zhanhua Gao, Di Chen, Jie Han, Guanyue Xie, Jianguang Sun
BMC Cancer.2025;[Epub] CrossRef
Impact of Dietary Behavioural Changes on Prognosis of Postoperative Oesophageal Squamous Cell Carcinoma Patients: A Retrospective Cohort Study
Fengqing Ji, Yunyun Chen, Yan Ma, Haiyan Wu, Xinqi Wei, Zhiyun Xu, Jianqiang Zhao
Nursing Open.2025;[Epub] CrossRef
Health Outcomes Associated with Hypolipidemia: a Scoping Review
Seungcheol Hong, Dong-jun Choi, Ji-cheon Jeong
The Journal of Internal Korean Medicine.2025; 46(1): 61. CrossRef
Association between Metabolically Healthy Status and Risk of Gastrointestinal Cancer
Haozhe Cui, Fei Tian, Yongliang Chen, Xiangming Ma
Cancer Research and Treatment.2024; 56(1): 238. CrossRef
Identification of structural motifs critical for human G6PC2 function informed by sequence analysis and an AlphaFold2-predicted model
Emily M. Hawes, Derek P. Claxton, James K. Oeser, Richard M. O’Brien
Bioscience Reports.2024;[Epub] CrossRef
Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population
Matthieu Wargny, Thomas Goronflot, Antoine Rimbert, Jérôme Boursier, Sofiane Kab, Joseph Henny, Antoine Lainé, Christophe Leux, Sarra Smati, Samy Hadjadj, Cédric Le May, Marcel Goldberg, Marie Zins, Bertrand Cariou
Journal of Hepatology.2024; 80(6): 846. CrossRef
Biochemical and metabolic characterization of a G6PC2 inhibitor
Emily M. Hawes, Mohsin Rahim, Zeinab Haratipour, Abigail R. Orun, Margaret L. O'Rourke, James K. Oeser, Kwangho Kim, Derek P. Claxton, Ray D. Blind, Jamey D. Young, Richard M. O'Brien
Biochimie.2024; 222: 109. CrossRef
Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors
Hao Li, Shuai Wang, Zhengqiang Yang, Xianwei Meng, Meng Niu
Bioactive Materials.2024; 36: 376. CrossRef
Association between transitions in metabolic health and colorectal cancer across categories of body size phenotype: a prospective cohort study
Qian Liu, Fei Si, Yuntao Wu, Jing Yu
Obesity.2024; 32(10): 1948. CrossRef
Prognostic value of AFP-L3 and Des-γ-carboxy prothrombin in advanced primary liver cancer treated with Sorafenib and transarterial chemoembolization
Shiwen Tang
American Journal of Translational Research.2024; 16(9): 5004. CrossRef
Abdominal obesity, chronic inflammation and the risk of non-alcoholic fatty liver disease
Dongna Zhao, Haozhe Cui, Zhiqiang Shao, Liying Cao
Annals of Hepatology.2023; 28(4): 100726. CrossRef
Fasting plasma glucose and alanine aminotransferase on the risk of hepatocellular carcinoma: A nested case-control study
Lizhen Zhang, Zhongge Wang, Ruirui Chen, Zhiyuan Cheng, Jingli Yang, Jing Li, Siyu Li, Yarong Chen, Lulu Xu, Yujia Hu, Yana Bai
Cancer Epidemiology.2023; 84: 102362. CrossRef
Lipids, cholesterols, statins and liver cancer: a Mendelian randomization study
Zicheng Liang, Zhen Zhang, Xiaoning Tan, Puhua Zeng
Frontiers in Oncology.2023;[Epub] CrossRef
Triglyceride-glucose index associated with the risk of cardiovascular disease: the Kailuan study
Qian Liu, Haozhe Cui, Yihan Ma, Xu Han, Zhiwei Cao, Yuntao Wu
Endocrine.2022; 75(2): 392. CrossRef
Cumulative triglyceride-glucose index is a risk for CVD: a prospective cohort study
Haozhe Cui, Qian Liu, Yuntao Wu, Liying Cao
Cardiovascular Diabetology.2022;[Epub] CrossRef
Association of triglyceride–glucose index and traditional risk factors with cardiovascular disease among non-diabetic population: a 10-year prospective cohort study
Li Liu, Zhenguo Wu, Yifan Zhuang, Yerui Zhang, Huiliang Cui, Fanghong Lu, Jie Peng, Jianmin Yang
Cardiovascular Diabetology.2022;[Epub] CrossRef

7,187 View
121 Download
16 Web of Science
17 Crossref

General

Trends in Cancer Screening Rates among Korean Men and Women: Results of the Korean National Cancer Screening Survey, 2004–2018: Seri Hong, Yun Yeong Lee, Jaeho Lee, Yeol Kim, Kui Son Choi, Jae Kwan Jun, Mina Suh; Cancer Res Treat. 2021;53(2):330-338. Published online October 20, 2020; DOI: https://doi.org/10.4143/crt.2020.263

Abstract PDF Supplementary Material PubReader ePub

Purpose
The Korean National Cancer Screening Survey (KNCSS) is a nationwide annual cross-sectional survey conducted for the past 15 years. This study aimed to report trends in the overall screening rates of both organized and opportunistic cancer screening programs from 2004–2018.
Materials and Methods
KNCSS data were collected using a structured questionnaire. For five major cancers (i.e., stomach, liver, colorectal, breast, and cervical cancer), we evaluated both the lifetime screening rate and the screening rate with recommendations. The study population included men aged 40–74 years and women aged 20–74 years with no cancer histories.
Results
Screening rate with recommendations increased from 2004 annually by 4.4% and 1.5% until 2013 for stomach and liver cancers, respectively, by 4.0% until 2012 for breast cancer, and by 3.6% and 1.2% until 2014 for colorectal and cervical cancers, respectively, followed by nonsignificant trends thereafter. In 2018, screening rates with recommendations for these cancers were 72.8%, 26.2%, 63.1%, 58.4%, and 55.6%, respectively.
Conclusion
Screening rates for the five types of cancer demonstrated a marked increase between 2004 and 2018. However, many recent screening rates have been flattened with nonsignificant trends, and there are lower rates for cervical cancer screening among young age groups. Steady efforts are needed to achieve higher screening participation rates overall, especially for the cervical cancer screening of young women in their 20s.

Citations

Citations to this article as recorded by

A cross-national investigation of CT, MRI, PET, mammography, and radiation therapy resources and utilization
Takahiro Aoyama, Yutaro Koide, Hidetoshi Shimizu, Atsushi Urikura, Tomoki Kitagawa, Shingo Hashimoto, Hiroyuki Tachibana, Takeshi Kodaira
Japanese Journal of Radiology.2025; 43(1): 109. CrossRef
Current and future burden of breast cancer in Asia: A GLOBOCAN data analysis for 2022 and 2050
Mengxia Fu, Zhiming Peng, Min Wu, Dapeng Lv, Yanping Li, Shuzhen Lyu
The Breast.2025; 79: 103835. CrossRef
Trends in Cancer-Screening Rates in Korea: Findings from the National Cancer Screening Survey, 2004-2023
EunKyo Kang, Kui Son Choi, Jae Kwan Jun, Yeol Kim, Hyeon Ji Lee, Chang Kyun Choi, Tae Hee Kim, Sun Hwa Lee, Mina Suh
Cancer Research and Treatment.2025; 57(1): 28. CrossRef
Korean Gastric Cancer Association-Led Nationwide Survey on Surgically Treated Gastric Cancers in 2023
Dong Jin Kim, Jeong Ho Song, Ji-Hyeon Park, Sojung Kim, Sin Hye Park, Cheol Min Shin, Yoonjin Kwak, Kyunghye Bang, Chung-sik Gong, Sung Eun Oh, Yoo Min Kim, Young Suk Park, Jeesun Kim, Ji Eun Jung, Mi Ran Jung, Bang Wool Eom, Ki Bum Park, Jae Hun Chung, S
Journal of Gastric Cancer.2025; 25(1): 115. CrossRef
Association Between Levonorgestrel-Releasing Intrauterine System Exposure Duration and Breast Cancer Incidence
Jin-Sung Yuk, Myoung Hwan Kim, Sang Hee Yoon, Gwan Hee Han, Ji Hyun Noh
Obstetrics & Gynecology.2025; 145(5): 523. CrossRef
Determinants of Prostate Cancer Screening in Korean Men: A Nationwide Study Using the Korean National Cancer Screening Survey 2023
Giap Viet Nguyen, Kyeongmin Lee, Hyeon Ji Lee, EunKyo Kang, Mina Suh, Jae Kwan Jun, Kui Son Choi
Cancer Research and Treatment.2025; 57(2): 539. CrossRef
The Effect of Nationwide Organized Cancer Screening Programs on Gastric Cancer Mortality: A Synthetic Control Study
Dianqin Sun, Duco T. Mülder, Yige Li, Daan Nieboer, Jin Young Park, Mina Suh, Chisato Hamashima, Weiran Han, James F. O’Mahony, Iris Lansdorp-Vogelaar
Gastroenterology.2024; 166(3): 503. CrossRef
Population‐based evaluation of disparities in stomach cancer by nativity among Asian and Hispanic populations in California, 2011–2015
Eunjung Lee, Kai‐Ya Tsai, Juanjuan Zhang, Amie E. Hwang, Dennis Deapen, Jennifer J. Koh, Eric S. Kawaguchi, James Buxbaum, Sang Hoon Ahn, Lihua Liu
Cancer.2024; 130(7): 1092. CrossRef
Socio-economic factors and medical conditions affecting regular stomach cancer screening in Korea: a retrospective longitudinal study using national public health data for 11 years
J.-Y. Kim, J.Y. Hong, S.M. Kim, K.H. Ryu, D.S. Kim, S.H. Lee, J.H. Na, H.H. Cho, J. Yu, J. Lee
Public Health.2024; 227: 70. CrossRef
Relationship between menopausal hormone therapy and breast cancer: A nationwide population‐based cohort study
Jin‐Sung Yuk
International Journal of Gynecology & Obstetrics.2024; 166(2): 735. CrossRef
Risk of Subsequent Primary Cancers Among Adult-Onset 5-Year Cancer Survivors in South Korea: Retrospective Cohort Study
Yoon Young Choi, Myeongjee Lee, Eun Hwa Kim, Jae Eun Lee, Inkyung Jung, Jae-Ho Cheong
JMIR Public Health and Surveillance.2024; 10: e48380. CrossRef
Association between low-dose aspirin and the risk of gastric cancer and adenoma according to a family history of gastric cancer
Yoon Suk Jung, Mai Thi Xuan Tran, Boyoung Park, Chang Mo Moon
Digestive and Liver Disease.2024; 56(9): 1614. CrossRef
Temporal Trend in Uptake of the National General Health Checkups and Cancer Screening Program among Korean Women with Breast Cancer
Thi Xuan Mai Tran, Soyeoun Kim, Chihwan Cha, Boyoung Park
Cancer Research and Treatment.2024; 56(2): 522. CrossRef
Association between Gastric Cancer and Osteoporosis: A Longitudinal Follow-Up Study Using a National Health Sample Cohort
Kyeong Min Han, Mi Jung Kwon, Joo-Hee Kim, Ji Hee Kim, Woo Jin Bang, Hyo Geun Choi, Dae Myoung Yoo, Na-Eun Lee, Nan Young Kim, Ho Suk Kang
Cancers.2024; 16(13): 2291. CrossRef
Trends in breast density and other risk factors for breast cancer and associations with trends in the incidence of breast cancer in Korean women
Soyeoun Kim, Thi Xuan Mai Tran, Boyoung Park
Maturitas.2024; 189: 108070. CrossRef
National Statistics of Endoscopic Submucosal Dissection for Early Gastric Cancer in Korea
Sang Hoon Lee, Hyunseok Cho, Myoung-Nam Lim, Seung-Joo Nam
Journal of Gastric Cancer.2024; 24(4): 464. CrossRef
Public awareness of gastric cancer risk factors and screening behaviours in Shijiazhuang, China: A community-based survey
Qian Wang, Xiao-Ci He, Lian-Xia Geng, Shu-Lin Jiang, Chuan-Jie Yang, Kai-Yue Xu, Shu-Fang Shen, Wen-Wen Cao, Wei Qi, Shu-Ping Zhao, Pengpeng Ye
PLOS ONE.2024; 19(10): e0311491. CrossRef
Pattern Anlysis of Risk-Reducing Strategies in Unaffected Korean BRCA1/2 Mutation Carriers
Dabin Kim, Jai Min Ryu, Sang-Ah Han, Zisun Kim, Sung-Won Kim
Current Oncology.2024; 31(11): 6767. CrossRef
Effectiveness of the Korean National Cancer Screening Program in Reducing Colorectal Cancer Mortality
Hyeon Ji Lee, Kyeongmin Lee, Byung Chang Kim, Jae Kwan Jun, Kui Son Choi, Mina Suh
Cancers.2024; 16(24): 4278. CrossRef
The Significant Predictors for Breast, Cervical, Colorectal, or Oral Cancer Screening Intention and Behavior in Taiwan
Hsiu-Chen Huang, Pei-Chi Chang, Sin-Fong Li, Cing-Ya Wang, Wan-Ting Huang, Wei Chen, Sheng-Yu Fan
Cancer Nursing.2023; 46(4): E261. CrossRef
Increasing disparities in the proportions of active treatment and 5-year overall survival over time by age groups among older patients with gastric cancer in Korea
Hyun-Soo Zhang, Dong-Woo Choi, Han Sang Kim, Hye Jung Kang, Hoyol Jhang, Wonjeong Jeong, Chung Mo Nam, Sohee Park
Frontiers in Public Health.2023;[Epub] CrossRef
Changing trends in the incidence and spectrum of cancers between 1990 and 2021 among HIV-infected patients in Busan, Korea
Soon Ok Lee, Jeong Eun Lee, Yong Ki Sim, Shinwon Lee, Woo Seog Ko, Jinmi Kim, Jin Suk Kang, Hyunjin Son, Sun Hee Lee
Journal of Infection and Chemotherapy.2023; 29(6): 571. CrossRef
Positive faecal immunochemical test predicts the onset of inflammatory bowel disease: A nationwide, propensity score-matched study
Eunyoung Lee, Gil Ho Lee, Bumhee Park, Sung Soo Ahn, Choong-Kyun Noh
Frontiers in Immunology.2023;[Epub] CrossRef
Local Recurrence after Endoscopic Submucosal Dissection of Early Gastric Cancer
Dae-Gon Ryu, Su-Jin Kim, Cheol-Woong Choi, Su-Bum Park, Hyeong-Seok Nam, Si-Hak Lee, Sun-Hwi Hwang
Journal of Clinical Medicine.2023; 12(5): 2018. CrossRef
Association of Breast Cancer Family History With Breast Density Over Time in Korean Women
Thi Xuan Mai Tran, Yoosoo Chang, Soyeoun Kim, Huiyeon Song, Seungho Ryu, Boyoung Park
JAMA Network Open.2023; 6(3): e232420. CrossRef
Risk of upper gastrointestinal cancer and death in persons with negative screening results: results from the National Cancer Screening Program in South Korea
Xuan Quy Luu, Kyeongmin Lee, Jae Kwan Jun, Mina Suh, Kyu-Won Jung, Il Ju Choi, Kui Son Choi
Gastric Cancer.2023; 26(4): 580. CrossRef
Changes in cervical dysplasia, carcinoma in situ, and cervical cancer after expanding the National Cancer Screening Program to younger women in Korea
Woorim Kim, Sungyoun Chun, Sang Ah Lee
International Journal for Quality in Health Care.2023;[Epub] CrossRef
Elevated risk of cervical cancer in elderly women with incident ulcerative colitis in South Korea
Jihoon Kim, Halim Jo, Min Chul Ha, Hyunil Kim, Jung Kuk Lee, Jae Hun Han, San-Hui Lee, Dae Ryong Kang, Su Young Kim, Hyun-Soo Kim, Hee Man Kim
Scientific Reports.2023;[Epub] CrossRef
Mutual association between family history of gastric and colorectal cancer and risk of gastric and colorectal cancer
Yoon Suk Jung, Mai Thi Xuan Tran, Boyoung Park, Chang Mo Moon
Journal of Gastroenterology and Hepatology.2023; 38(10): 1787. CrossRef
Overview of the National Cancer Screening Program for Colorectal Cancer in Korea over 14 Years (2004-2017)
Bomi Park, Eun Young Her, Kyeongmin Lee, Fatima Nari, Jae Kwan Jun, Kui Son Choi, Mina Suh
Cancer Research and Treatment.2023; 55(3): 910. CrossRef
Impact of health disparities on national breast cancer screening participation rates in South Korea
Fatima Nari, Juwon Park, Nayeon Kim, Dong Jin Kim, Jae Kwan Jun, Kui Son Choi, Mina Suh
Scientific Reports.2023;[Epub] CrossRef
Socioeconomic inequality in organized and opportunistic screening for gastric cancer: results from the Korean National Cancer Screening Survey 2009–2022
Xuan Quy Luu, Kyeongmin Lee, Jae Kwan Jun, Mina Suh, Kui Son Choi
Frontiers in Public Health.2023;[Epub] CrossRef
The impact of stomach cancer mortality on life expectancy at birth: a decomposition analysis in east Asian countries from 1990 to 2019
Chunyong Chen, Leiwen Jiang, Siying Lyu, Guillaume Marois
China Population and Development Studies.2023; 7(4): 325. CrossRef
Parental intention to vaccinate daughters with the human papillomavirus vaccine in Korea: a nationwide cross-sectional survey
Yejin Ha, Kyeongmin Lee, Bomi Park, Mina Suh, Jae Kwan Jun, Kui Son Choi
Epidemiology and Health.2023; 45: e2023076. CrossRef
Socioeconomic inequality in organized and opportunistic screening for colorectal cancer: results from the Korean National Cancer Screening Survey, 2009-2021
Xuan Quy Luu, Kyeongmin Lee, Jae Kwan Jun, Mina Suh, Kui Son Choi
Epidemiology and Health.2023; 45: e2023086. CrossRef
Changes in weight and waist circumference during menopausal transition and postmenopausal breast cancer risk
Boyoung Park
International Journal of Cancer.2022; 150(9): 1431. CrossRef
Trends in cervical cancer screening rates among Korean women: results of the Korean National Cancer Screening Survey, 2005–2020
Hye Young Shin, Yun Yeong Lee, Soo Yeon Song, Bomi Park, Mina Suh, Kui Son Choi, Jae Kwan Jun
Journal of Gynecologic Oncology.2022;[Epub] CrossRef
Impact of preceding noncurative endoscopic submucosal dissection on patients with early gastric cancer who undergo subsequent surgery: a meta-analysis
Jian Jiao, Han Li, Liang Shang, Huicheng Ren, Chunshui Ye, Ronghua Zhang, Kun Xiao, Kangdi Dong, Jin Liu, Leping Li
Expert Review of Gastroenterology & Hepatology.2022; 16(4): 373. CrossRef
Relationship between histological mixed-type early gastric cancer and lymph node metastasis: A systematic review and meta-analysis
Shufan Yang, Xin Gu, Rui Tao, Jiahui Huo, Zhen Hu, Fei Sun, Jinbin Ni, Xiaoyun Wang, Girijesh Kumar Patel
PLOS ONE.2022; 17(4): e0266952. CrossRef
Mammographic breast density, body mass index and risk of breast cancer in Korean women aged 75 years and older
Thi Xuan Mai Tran, Soyeoun Kim, Huiyeon Song, Boyoung Park
International Journal of Cancer.2022; 151(6): 869. CrossRef
Current status of the gastric cancer screening program in Korea
Young-Il Kim, Il Ju Choi
Journal of the Korean Medical Association.2022; 65(5): 250. CrossRef
Nationwide population-based incidence of cancer among patients with HIV/AIDS in South Korea
Soon Ok Lee, Jeong Eun Lee, Shinwon Lee, Sun Hee Lee, Jin Suk Kang, Hyunjin Son, Hyungi Lee, Jinmi Kim
Scientific Reports.2022;[Epub] CrossRef
Impact of COVID-19 on cancer screening in South Korea
Kyeonmin Lee, Yun Yeong Lee, Mina Suh, Jae Kwan Jun, Bomi Park, Yeol Kim, Kui Son Choi
Scientific Reports.2022;[Epub] CrossRef
Current Evidence for a Paradigm Shift in Gastric Cancer Prevention From Endoscopic Screening toHelicobacter pyloriEradication in Korea
Young-Il Kim, Il Ju Choi
Journal of Gastric Cancer.2022; 22(3): 169. CrossRef
Epidemiology of Gastric Cancer in Korea: Trends in Incidence and Survival Based on Korea Central Cancer Registry Data (1999–2019)
Sin Hye Park, Mee Joo Kang, E Hwa Yun, Kyu-Won Jung
Journal of Gastric Cancer.2022; 22(3): 160. CrossRef
Association Between Family History of Gastric Cancer and the Risk of Gastric Cancer and Adenoma: A Nationwide Population-Based Study
Yoon Suk Jung, Mai Thi Xuan Tran, Boyoung Park, Chang Mo Moon
American Journal of Gastroenterology.2022; 117(8): 1255. CrossRef
Third Asia-Pacific consensus recommendations on colorectal cancer screening and postpolypectomy surveillance
Joseph J Y Sung, Han-Mo Chiu, David Lieberman, Ernst J Kuipers, Matthew D Rutter, Finlay Macrae, Khay-Guan Yeoh, Tiing Leong Ang, Vui Heng Chong, Sneha John, Jingnan Li, Kaichun Wu, Simon S M Ng, Govind K Makharia, Murdani Abdullah, Nozomu Kobayashi, Masa
Gut.2022; 71(11): 2152. CrossRef
Family history of breast cancer, mammographic breast density and breast cancer risk: Findings from a cohort study of Korean women
Thi Xuan Mai Tran, Soyeoun Kim, Huiyeon Song, Boyoung Park
The Breast.2022; 65: 180. CrossRef
Longitudinal Changes in Smoking Habits in Women and Subsequent Risk of Cancer
Thi Xuan Mai Tran, Soyeoun Kim, Huiyeon Song, Boyoung Park
American Journal of Preventive Medicine.2022; 63(6): 894. CrossRef
The Prediction of Survival Outcome and Prognosis Factor in Association with Comorbidity Status in Patients with Colorectal Cancer: A Research-Based Study
Hafeez Afolabi, Salzihan Md Salleh, Zaidi Zakaria, Ewe Seng Ch’ng, Siti Norasikin Mohd Nafi, Ahmad Aizat Bin Abdul Aziz, Sameer Badri Al-Mhanna, Yusuf Wada, Abdulwali Sabo Abdulrahman
Healthcare.2022; 10(9): 1693. CrossRef
Association between A Family History of Colorectal Cancer and the Risk of Colorectal Cancer: A Nationwide Population-Based Study
Yoon Suk Jung, Huiyeon Song, Mai Thi Xuan Tran, Boyoung Park, Chang Mo Moon
Journal of Personalized Medicine.2022; 12(10): 1566. CrossRef
Income Disparity in Breast Cancer Incidence and Stage at Presentation: A National Population Study of South Korea
Seung-Ah Choe, Minji Roh, Hye Ri Kim, Soohyeon Lee, Myung Ki, Domyung Paek, Mia Son
Journal of Breast Cancer.2022; 25(5): 415. CrossRef
Analysis of HR-HPV Infection Concordance Rates in Cervical and Urine Specimens; Proposal of Additional Cervical Screening Process for Women Who Refuse Invasive Cervical Sampling
Dong Hyeok Kim, Hyunwoo Jin, Kyung Eun Lee
Journal of Personalized Medicine.2022; 12(12): 1949. CrossRef
Association of Late Marriage and Low Childbirth with Cervical Cancer Screening among Korean Women: Results from a Nationwide Survey
Hye Young Shin, Bomi Park, Mina Suh, Kui Son Choi, Jae Kwan Jun
Cancers.2022; 14(2): 327. CrossRef
Presentation of benefits and harms in cancer screening guidelines for Koreans: a systematic review protocol
Mi Ah Han, Jae Hung Jung, Eu Chang Hwang
BMJ Open.2022; 12(12): e065924. CrossRef
Effect of Pap smears on the long-term survival of cervical cancer patients: a nationwide population-based cohort study in Korea
Xuan Quy Luu, Kyeongmin Lee, Jae Kwan Jun, Mina Suh, kyu-won Jung, Myong Cheol Lim, Kui Son Choi
Epidemiology and Health.2022; 44: e2022072. CrossRef
Awareness of and practice toward cancer prevention recommendations: results of the Korean National Cancer Prevention Awareness and Practice Survey in 2021
Jin-Kyoung Oh, Eunjung Park, Byungmi Kim, Yoon-Jung Choi, E Hwa Yun, Min Kyung Lim, Jeong-Soo Im, Eun Young Park
Epidemiology and Health.2022; 44: e2022068. CrossRef
Effect of mammography screening on the long-term survival of breast cancer patients: results from the National Cancer Screening Program in Korea
Xuan Quy Luu, Kyeongmin Lee, Jae Kwan Jun, Mina Suh, Kyu-Won Jung, Kui Son Choi
Epidemiology and Health.2022; 44: e2022094. CrossRef
Changes in cancer screening before and during COVID‐19: findings from the Korean National Cancer Screening Survey 2019 and 2020
Thao Thi Kim Trinh, Yun Yeong Lee, Mina Suh, Jae Kwan Jun, Kui Son Choi
Epidemiology and Health.2022; 44: e2022051. CrossRef
Trends in breast cancer screening rates among Korean women: results from the Korean National Cancer Screening Survey, 2005-2020
Soo Yeon Song, Yun Yeong Lee, Hye Young Shin, Bomi Park, Mina Suh, Kui Son Choi, Jae Kwan Jun
Epidemiology and Health.2022; 44: e2022111. CrossRef
The impact of COVID-19 on screening for colorectal, gastric, breast, and cervical cancer in Korea
Hyeree Park, Seung Hee Seo, Jong Heon Park, Shin Hye Yoo, Bhumsuk Keam, Aesun Shin
Epidemiology and Health.2022; 44: e2022053. CrossRef
A nationwide survey on the effectiveness of training on endoscope reprocessing within the national cancer screening program in Korea
Hye Young Shin, Da Hun Jang, Jae Kwan Jun
American Journal of Infection Control.2021; 49(8): 1031. CrossRef
Current indications for endoscopic submucosal dissection of early gastric cancer
Zhi Zheng, Jie Yin, Xiao-Ye Liu, Xiao-Sheng Yan, Rui Xu, Meng-Yi Li, Jun Cai, Guang-Yong Chen, Jun Zhang, Zhong-Tao Zhang
World Journal of Gastrointestinal Oncology.2021; 13(6): 560. CrossRef
Effectiveness of the Korean National Cancer Screening Program in reducing breast cancer mortality
Eunji Choi, Jae Kwan Jun, Mina Suh, Kyu-Won Jung, Boyoung Park, Kyeongmin Lee, So-Youn Jung, Eun Sook Lee, Kui Son Choi
npj Breast Cancer.2021;[Epub] CrossRef
International comparison of trends in cancer mortality: Japan has fallen behind in screening-related cancers
Kota Katanoda, Yuri Ito, Tomotaka Sobue
Japanese Journal of Clinical Oncology.2021; 51(11): 1680. CrossRef
Korean Gastric Cancer Association-Led Nationwide Survey on Surgically Treated Gastric Cancers in 2019

Journal of Gastric Cancer.2021; 21(3): 221. CrossRef
Barriers and strategies for cervical cancer screening: What do female university students know and want?
Hye Young Shin, Soo Yeon Song, Jae Kwan Jun, Ka Young Kim, Purum Kang, Nülüfer Erbil
PLOS ONE.2021; 16(10): e0257529. CrossRef
The classification capability of the Asia Pacific Colorectal Screening score in Korea: an analysis of the Cancer Screenee Cohort
Xuan Quy Luu, Kyeongmin Lee, Jeongseon Kim, Dae Kyung Sohn, Aesun Shin, Kui Son Choi
Epidemiology and Health.2021; 43: e2021069. CrossRef

13,243 View
339 Download
70 Web of Science
68 Crossref

Factors Influencing Imatinib-Induced Hepatotoxicity: Ji Min Han, Jeong Yee, Yoon Sook Cho, Hye Sun Gwak; Cancer Res Treat. 2020;52(1):181-188. Published online June 26, 2019; DOI: https://doi.org/10.4143/crt.2019.131

Abstract PDF PubReader ePub

Purpose
Although imatinib-induced hepatotoxicity may aggravate the patient’s clinical condition and alter the treatment plan, the underlying mechanism of and factors influencing imatinibinduced hepatotoxicity have rarely been investigated. The purpose of this study was to investigate factors affecting on the incidence of hepatotoxicity within 90 days after starting imatinib treatment and time to onset of imatinib-induced hepatotoxicity.
Materials and Methods
We retrospectively evaluated the records of 177 patients receiving imatinib from October 2012 to September 2017. The analyzed factors included sex, age, body weight, body surface area, underlying disease, and concomitant drugs.
Results
The proportion of patients with hepatotoxicity within 90 days after imatinib administration was 33.9%. Proton pump inhibitors (PPIs) increased the incidence of hepatotoxicity approximately 3.8-fold and doubled the hazard of time to reach hepatotoxicity. Patients with liver disease or hepatitis B virus (HBV) carriers had a more than 8-fold higher risk of hepatotoxicity and a 5.2-fold increased hazard of hepatotoxicity compared to those without liver disease or HBV. Patients with body weight under 55 kg had a 2.2-fold higher risk for occurrence of hepatotoxicity. Patients with an imatinib dose > 400 mg had a 2.3-fold increased hazard of time to reach hepatotoxicity compared to those with an imatinib dose ≤ 400 mg.
Conclusion
The findings of this study suggest that the use of PPIs and presence of liver disease or HBV were associated with imatinib-induced hepatotoxicity. Thus, close liver function monitoring is recommended, especially in patients with liver impairment or using PPIs.

Citations

Citations to this article as recorded by

Efficient treatment of colon cancer with codelivery of TRAIL and imatinib by liposomes
Rongrong Fu, Rui Chang, Andong Peng, Changshun Feng, Weifan Zhu, Yi Chen, Xue Tian, Rui Wang, Hui Yan, Dianlong Jia, Jun Li
Pharmaceutical Development and Technology.2024; 29(1): 52. CrossRef
The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review
Mansour Tobaiqy, Nawal Helmi, Katie MacLure, Sylvia Saade
International Journal of Clinical Pharmacy.2024; 46(2): 368. CrossRef
Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis
Emilia Neuwirt, Giovanni Magnani, Tamara Ćiković, Svenja Wöhrle, Larissa Fischer, Anna Kostina, Stephan Flemming, Nora J. Fischenich, Benedikt S. Saller, Oliver Gorka, Steffen Renner, Claudia Agarinis, Christian N. Parker, Andreas Boettcher, Christopher J
Science Signaling.2023;[Epub] CrossRef
NLRP3 and cancer: Pathogenesis and therapeutic opportunities
Isak W. Tengesdal, Charles A. Dinarello, Carlo Marchetti
Pharmacology & Therapeutics.2023; 251: 108545. CrossRef
Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms
Shubhrat Purwar, Anam Fatima, Himashree Bhattacharyya, Lakshmi Venkata Simhachalam Kutikuppala, Matei-Alexandru Cozma, Bahadar Singh Srichawla, Leah Komer, Khulud Mahmood Nurani, Mihnea-Alexandru Găman
World Journal of Hepatology.2023; 15(9): 1021. CrossRef
Imatinib-induced hepatotoxicity via oxidative stress and activation of NLRP3 inflammasome: an in vitro and in vivo study
Feng-Ru Huang, Wen-Tong Fang, Zi-Ping Cheng, Ye Shen, Dun-Jian Wang, Yong-Qing Wang, Lu-Ning Sun
Archives of Toxicology.2022; 96(4): 1075. CrossRef
A Risk Scoring System Utilizing Machine Learning Methods for Hepatotoxicity Prediction One Year After the Initiation of Tyrosine Kinase Inhibitors
Ji Min Han, Jeong Yee, Soyeon Cho, Min Kyoung Kim, Jin Young Moon, Dasom Jung, Jung Sun Kim, Hye Sun Gwak
Frontiers in Oncology.2022;[Epub] CrossRef
Drug‐Drug Interactions and Disease Status Are Associated With Irinotecan‐Induced Hepatotoxicity: A Cross‐Sectional Study in Shanghai
Juan Li, Bing Chen, Wen‐qi Xi, Wan Jia, Wei‐xia Zhang, Xiao‐lan Bian
The Journal of Clinical Pharmacology.2022; 62(9): 1160. CrossRef
A new strategy for the rapid identification and validation of direct toxicity targets of psoralen-induced hepatotoxicity
Sitong Sun, Manshu Wang, Yu Yuan, Shuo Wang, Haoran Ding, Chenrui Liang, Xiaomeng Li, Simiao Fan, Yubo Li
Toxicology Letters.2022; 363: 11. CrossRef
Effects of High-Dose of Copper Amino Acid Complex on Laying Performance, Hematological and Biochemical Parameters, Organ Index, and Histopathology in Laying Hens
Qin Zhou, Jiaming Zhu, Bing Liu, Jialing Qiu, Xintao Lu, Brian Curtin, Fei Ji, Dongyou Yu
Biological Trace Element Research.2021; 199(8): 3045. CrossRef
Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile
Debasish Basak, Scott Arrighi, Yasenya Darwiche, Subrata Deb
Life.2021; 12(1): 48. CrossRef
Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study
Ji Min Han, Hye Won Han, Jeong Yee, Min Kyoung Kim, Jin Young Moon, Soyeon Cho, Dasom Jung, Yoon Sook Cho, Inyoung Seo, Jae Youn Kim, Hye Sun Gwak
European Journal of Clinical Pharmacology.2020; 76(8): 1183. CrossRef

7,626 View
233 Download
14 Web of Science
12 Crossref

Surveillance Rate and its Impact on Survival of Hepatocellular Carcinoma Patients in South Korea: A Cohort Study: Sanghyuk Im, Eun Sun Jang, Ju Hyun Lee, Chung Seop Lee, Beom Hee Kim, Jung Wha Chung, Jin-Wook Kim, Sook-Hyang Jeong; Cancer Res Treat. 2019;51(4):1357-1369. Published online February 12, 2019; DOI: https://doi.org/10.4143/crt.2018.430

Abstract PDF Supplementary Material PubReader ePub

Purpose
Though regular surveillance of hepatocellular carcinoma (HCC) for high-risk patients is widely recommended, its rate and effectiveness are not clear. The aim of this study is to investigate the actual rate of HCC surveillance and its related factors and to clarify its impact on survival in a Korean HCC cohort.
Materials and Methods
From 2012 to 2015, 319 newly diagnosed HCC patients were prospectively enrolled at a tertiary hospital. Patient interviews based on a structured questionnaire survey were conducted. Surveillance was defined as liver imaging test ≥ 2 times with at least 3-month interval within 2 years prior to HCC diagnosis.
Results
Surveillance rate was 39.8%. Of the HCC patients with high-risk factors, only 182 (57.1%) had knowledge for the need for regular surveillance, and 141 (44.2%) had the accurate information about the method (ultrasound-based study). Surveillance group showed a higher proportion of early HCC (p < 0.001) and a longer overall survival (p < 0.001) compared to non-surveillance group. The multivariable Cox regression analysis indicated Child-Pugh class A, history of anti-viral therapy, low serum α-fetoprotein level, non-advanced Barcelona Clinic Liver Cancer stage as independent predictors of overall survival, while regular surveillance was not (p=0.436).
Conclusion
Less than half of the newly diagnosed Korean HCC patients were under surveillance and the accurate perception for the need of HCC surveillance was insufficient. Of those under surveillance, most patients were diagnosed with early stage HCC, which led to the improved survival. Comprehensive efforts to optimize the surveillance program for the target population are warranted.

Citations

Citations to this article as recorded by

Dedicated Automatic Recall Hepatocellular Cancer Surveillance Programme Demonstrates High Retention: A Population‐Based Cohort Study
Mayur Brahmania, Stephen Congly, Yashasavi Sachar, Kelly W. Burak, Brendan Lethebe, Jessie Hart Szostakiwskyj, David Lautner, Alexandra Medellin, Deepak Bhayana, Jason Wong, Henry Nguyen, Matthew D. Sadler, Meredith Borman, Alexander I. Aspinall, Carla S.
Liver International.2025;[Epub] CrossRef
Impact of Screening on Mortality for Patients Diagnosed with Hepatocellular Carcinoma in a Safety-Net Healthcare System: An Opportunity for Addressing Disparities
Kalyani Narra, Madison Hull, Kari J. Teigen, Vedaamrutha Reddy, Jolonda C. Bullock, Riyaz Basha, Nadia Alawi-Kakomanolis, David E. Gerber, Timothy J. Brown
Cancers.2024; 16(22): 3829. CrossRef
Benefits and harms of screening for hepatocellular carcinoma in high-risk populations: systematic review and meta-analysis
Jichun Yang, Zhirong Yang, Xueyang Zeng, Shuqing Yu, Le Gao, Yu Jiang, Feng Sun
Journal of the National Cancer Center.2023; 3(3): 175. CrossRef
Factors associated with the survival outcomes of patients with untreated hepatocellular carcinoma: An analysis of nationwide data
Min Jung Kwon, Soy Chang, Ji Hoon Kim, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Pil Soo Sung
Frontiers in Oncology.2023;[Epub] CrossRef
Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential implications for surveillance goal
Joo Hye Song, Myung Ji Goh, Yewan Park, Joo Hyun Oh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Scandinavian Journal of Gastroenterology.2021; 56(3): 274. CrossRef
Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study
Dong Hyun Sinn, Danbee Kang, Yun Soo Hong, Kwang Cheol Koh, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak, Luca Rinaldi
PLOS ONE.2021; 16(8): e0255624. CrossRef

8,006 View
212 Download
7 Web of Science
6 Crossref

Long-term Survival in Patients Treated with a Robotic Radiosurgical Device for Liver Metastases: Sebastian Stintzing, Jobst von Einem, Christoph Fueweger, Alfred Haidenberger, Michael Fedorov, Alexander Muavcevic; Cancer Res Treat. 2019;51(1):187-193. Published online April 16, 2018; DOI: https://doi.org/10.4143/crt.2017.594

Abstract PDF PubReader ePub

Purpose
The treatment of liver metastases with local procedures is a fast progressing field. For the most, long-term survival data is missing raising questions with regard to the efficacy of such modalities when compared to surgical resection. Radiosurgery using the CyberKnife device enables the treatment of liver lesions with a single-session approach. Here we present long-term survival data to explore the curative potential of this strategy.
Materials and Methods
Patients with oligo-metastatic disease limited to the liver have been treated with single-session or hypo-fractioned radiosurgery in curative intent and prospectively followed until death. Follow-up (FU) was performed using magnetic resonance imaging (MRI) 2 months after radiation and at 3-month intervals for the first 2 years. After that annual computed tomography or MRI scans were performed until 5 years post-treatment. Local recurrence in the radiated volume and recurrence outside the treated volume were used to define local and distant progression. Survival times were censored at the time of the last FU.
Results
One hundred twenty-six patients treated between 2005 and 2015 with 194 lesions were included into this study. Median FU was 30.0 months. According to Response Evaluation Criteria in Solid Tumors, 55.2% had a complete remission and 11.3% a partial remission. Seventy-two point two percent recurred outside the radiated lesion and median overall survival was 35.2 months with a 3-year survival rate of 47.7%.
Conclusion
This is currently the largest cohort of stereotactic body radiation therapy treated liver lesions with a median long-term follow of 30 months. Robotic radiosurgery using a single session approach has a high efficacy to control the radiated lesion with the potential to cure patients.

Citations

Citations to this article as recorded by

Stereotactic Body Radiation therapy for Liver Metastases: Systematic Review and Meta-Analysis With International Stereotactic Radiosurgery Society (ISRS) Practice Guidelines
Ciro Franzese, Alexander V. Louie, Rupesh Kotecha, Zhenwei Zhang, Matthias Guckenberger, Mi-Sook Kim, Alison C. Tree, Ben J. Slotman, Arjun Sahgal, Marta Scorsetti
Practical Radiation Oncology.2025; 15(2): e172. CrossRef
Prospective planning comparison of magnetic resonance-guided vs. internal target volume-based stereotactic body radiotherapy of hepatic metastases – Which patients do really benefit from an MR-linac?
Philipp Hoegen-Saßmannshausen, C. Katharina Renkamp, Hoi Hin Lau, David Neugebauer, Nina Niebuhr, Carolin Buchele, Fabian Schlüter, Elisabetta Sandrini, Line Hoeltgen, Fabian Weykamp, Sebastian Regnery, Jakob Liermann, Eva Meixner, Kevin Zhang, Oliver Sed
Clinical and Translational Radiation Oncology.2025; 52: 100941. CrossRef
Robotic Stereotactic Body Radiation Therapy for Oligometastatic Liver Metastases: A Systematic Review of the Literature and Evidence Quality Assessment
Ilektra Kyrochristou, Ilias Giannakodimos, Maria Tolia, Ioannis Georgakopoulos, Nikolaos Pararas, Francesk Mulita, Nikolaos Machairas, Dimitrios Schizas
Diagnostics.2024; 14(10): 1055. CrossRef
Effectiveness of Robotic Stereotactic Radiotherapy in Patients Undergoing Re-irradiation: A Review
Ahamed Badusha Mohamed Yoosuf, Salem Alshehri, Mohd Zahri Abdul Aziz, Syahir Mansor, Gokula Kumar Appalanaido, Mamdouh Alqathami
Cureus.2023;[Epub] CrossRef
Stereotactic body radiation therapy in patients with liver oligometastases from colorectal cancer: a systematic review
A. N. Moskalenko, V. K. Lyadov, I. V. Sagaydak, M. V. Chernykh, N. N. Britskaya
Pelvic Surgery and Oncology.2022; 12(1): 49. CrossRef
Anti-EGFR Therapy Induces EGF Secretion by Cancer-Associated Fibroblasts to Confer Colorectal Cancer Chemoresistance
Colleen M. Garvey, Roy Lau, Alyssa Sanchez, Ren X. Sun, Emma J. Fong, Michael E. Doche, Oscar Chen, Anthony Jusuf, Heinz-Josef Lenz, Brent Larson, Shannon M. Mumenthaler
Cancers.2020; 12(6): 1393. CrossRef

8,198 View
152 Download
6 Web of Science
6 Crossref

Hepatic Resection Provides Survival Benefit for Selected Intermediate-Stage (BCLC-B) Hepatocellular Carcinoma Patients: Zhang Zhaohui, Shen Shunli, Chen Bin, Li Shaoqiang, Hua Yunpeng, Kuang Ming, Liang Lijian, Peng Bao Gang; Cancer Res Treat. 2019;51(1):65-72. Published online February 26, 2018; DOI: https://doi.org/10.4143/crt.2018.038

Abstract PDF PubReader ePub

Purpose
The intermediate stage of hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer [BCLC] B) comprises a highly heterogeneous population, and the treatment strategy is still controversial. Because of the heterogeneity, a subclassification of intermediate-stage HCCs was put forward by Bolondi according to the ‘beyond Milan and within up-to-7’ criteria and Child-Pugh score. In this study, we aim to analyze the prognosis of BCLC-B stage HCC patients who received hepatic resection according to the Bolondi’s subclassification.
Materials and Methods
One thousand and one hundred three patients diagnosedwith HCC and treatedwith hepatic resectionwere enrolled in our hospital between 2006 and 2012. According to Bolondi’s subclassification, the BCLC-B patients were divided into four groups. Recurrence-free survival (RFS) and overall survival (OS) were analyzed.
Results
According to Bolondi’s subclassification, the BCLC-B patients were divided into four groups: B1 (n=41, 18.7%), B2 (n=160, 73.1%), B3 (n=11, 5.0%), and B4 (n=7, 3.2%). Significant difference was observed between B1 and other groups (B1 vs. B2, p=0.022; B1 vs. B3, p < 0.001; B1 vs. B4, p < 0.001), but no difference for B2 vs. B4 (p=0.542) and B3 vs. B4 (p=0.542). In addition, no significant differences were observed between BCLC-A and BCLC-B1 group for both RFS (p=0.087) and OS (p=0.643). In multivariate analysis, BCLC-B subclassification was not a risk factor for both OS (p=0.263) and RFS (p=0.892).
Conclusion
In our study, HCC patients at B1 stagewere benefited from hepatic resection and had similar survival to BCLC-A stage patients. Our study provided rationality of hepatic resection for selected BCLC-B stage HCC patients instead of routine transarterial chemoembolization.

Citations

Citations to this article as recorded by

Overexpression of tousled-like kinase 2 predicts poor prognosis in HBV-related hepatocellular carcinoma patients after radical resection
Bang Liu, Ling-Ling Lu, Li Yu, Xuan Mei, Jia Liu, Jiao-Long Zheng, Xiao-Ling Zhou, Hai-Yan Lin, Xiu-Ling Zhu, Dong-Liang Li
Frontiers in Genetics.2024;[Epub] CrossRef
Prognostic significance of early and multiple recurrences after curative resection for hepatocellular carcinoma
Akihiro Tanemura, Daisuke Noguchi, Toru Shinkai, Takahiro Ito, Aoi Hayasaki, Kazuyuki Gyoten, Takehiro Fujii, Yusuke Iizawa, Yasuhiro Murata, Naohisa Kuriyama, Masashi Kishiwada, Shugo Mizuno
BMC Surgery.2024;[Epub] CrossRef
TAC score better predicts survival than the BCLC following resection of hepatocellular carcinoma
Henrique A. Lima, Yutaka Endo, Zorays Moazzam, Laura Alaimo, Chanza Shaikh, Muhammad M. Munir, Vivian Resende, Alfredo Guglielmi, Hugo P. Marques, François Cauchy, Vincent Lam, George A. Poultsides, Irinel Popescu, Sorin Alexandrescu, Guillaume Martel, It
Journal of Surgical Oncology.2023; 127(3): 374. CrossRef
Multiplication of tumor maximum diameter and number as a new surgical indicator for Barcelona Clinic Liver Cancer intermediate‐stage hepatocellular carcinoma
Yuji Morine, Yu Saito, Shinichiro Yamada, Hiroki Teraoku, Yuhei Waki, Takayuki Noma, Tetsuya Ikemoto, Mitsuo Shimada
Hepatology Research.2023; 53(6): 531. CrossRef
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada
Jason K. Wong, Howard J. Lim, Vincent C. Tam, Kelly W. Burak, Laura A. Dawson, Prosanto Chaudhury, Robert J. Abraham, Brandon M. Meyers, Gonzalo Sapisochin, David Valenti, Setareh Samimi, Ravi Ramjeesingh, Amol Mujoomdar, Ilidio Martins, Elijah Dixon, Maj
Cancer Treatment Reviews.2023; 115: 102526. CrossRef
Advances in post-operative prognostic models for hepatocellular carcinoma
Ziqin He, Xiaomin She, Ziyu Liu, Xing Gao, Lu Lu, Julu Huang, Cheng Lu, Yan Lin, Rong Liang, Jiazhou Ye
Journal of Zhejiang University-SCIENCE B.2023; 24(3): 191. CrossRef
Preoperative alpha fetoprotein, total bilirubin, fibrinogen, albumin, and lymphocytes predict postoperative survival in hepatocellular carcinoma
Jia Xu, Shu An, Ying Lu, Laisheng Li, Zhi‐Qi Wu, Hua‐Guo Xu
Cancer Medicine.2023; 12(12): 13319. CrossRef
Liver resection versus transarterial chemoembolisation for the treatment of intermediate hepatocellular carcinoma: a systematic review and meta-analysis
Aleksandar Bogdanovic, Jelena Djokic Kovac, Predrag Zdujic, Uros Djindjic, Vladimir Dugalic
International Journal of Surgery.2023; 109(5): 1439. CrossRef
Surgical resection versus transarterial chemoembolization for patients with hepatocellular carcinoma beyond Milan criteria: prognostic role of tumor burden score
Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Yi-Hsiang Huang, Hao-Jan Lei, Jia-I Liao, Chien-Wei Su, Ming-Chih Hou, Teh-Ia Huo
Scientific Reports.2023;[Epub] CrossRef
Clinical outcome of surgical resection for multifocal T2-T3 hepatocellular carcinoma up to 3 nodules: a comparative analysis with a single nodule
Sehyeon Yu, Hye-Sung Jo, Young-Dong Yu, Yoo jin Choi, Dong-Sik Kim
Journal of Liver Cancer.2023; 23(2): 377. CrossRef
Pretreatment Non-Invasive Biomarkers as Predictors to Estimate Portal Vein Tumor Thrombosis (PVTT) Risk and Long-Term Survival in HBV-Related Hepatocellular Carcinoma Patients Without PVTT
Bang Liu, Jia Liu, Xuan Mei, Zhi-Qiang Zhang, Jian Fang, Li-Li Zhou, Jiao-Long Zheng, Hai-Yan Lin, Xiu-Ling Zhu, Dong-Liang Li
Journal of Hepatocellular Carcinoma.2023; Volume 10: 2367. CrossRef
Tumor Burden Score and Serum Alpha-fetoprotein Subclassify Intermediate-Stage Hepatocellular Carcinoma
Henrique A. Lima, Yutaka Endo, Laura Alaimo, Zorays Moazzam, Muhammad Musaab Munir, Chanza Shaikh, Vivian Resende, Alfredo Guglielmi, Hugo P. Marques, François Cauchy, Vincent Lam, George A. Poultsides, Irinel Popescu, Sorin Alexandrescu, Guillaume Martel
Journal of Gastrointestinal Surgery.2022; 26(12): 2512. CrossRef
Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma
Wei-Fan Hsu, Kai-Chih Chang, Te-Hong Chen, Chien-Hung Lin, Ying-Chun Lin, Ming-Hung Tsai, Pei-Yu Chen, Hung-Wei Wang, Chia-Sheng Chu, Cheng-Yuan Peng
Medicine.2021; 100(33): e27000. CrossRef
Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study
Linbin Lu, Peichan Zheng, Zhixian Wu, Xiong Chen
Frontiers in Oncology.2021;[Epub] CrossRef
Hepatocellular carcinoma surveillance, early detection and survival in a privately insured US cohort
Vincent L. Chen, Amit G. Singal, Elliot B. Tapper, Neehar D. Parikh
Liver International.2020; 40(4): 947. CrossRef
Complex treatment of hepatocellular carcinoma at early (BCLC-A) and intermediate (BCLC-B) stages
B. N. Kotiv, I. I. Dzidzava, S. A. Alent’yev, A. V. Smorodsky, K. I. Makhmudov, A. A. Apollonov, S. A. Soldatov, P. N. Zubarev
Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery.2020; 25(2): 55. CrossRef
A simple and clinically applicable model to predict liver-related morbidity after hepatic resection for hepatocellular carcinoma
Jonggi Choi, So-Hyun Kim, Seungbong Han, Danbi Lee, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Sung-Gyu Lee, Ki-Hun Kim, Kang Mo Kim, Leonidas G Koniaris
PLOS ONE.2020; 15(11): e0241808. CrossRef
BCLC-B Subclassification and the Hong Kong Liver Cancer System in Intermediate Hepatocellular Carcinoma
Larisse Longo, Laura B. Rodrigues de Freitas, Deivid Santos, Ivana Grivicich, Mário R. Álvares-da-Silva
American Journal of Clinical Oncology.2019; 42(5): 466. CrossRef

9,230 View
374 Download
21 Web of Science
18 Crossref

Proximal Resection Margins: More Prognostic than Distal Resection Margins in Patients Undergoing Hilar Cholangiocarcinoma Resection: Tae Yoo, Sang-Jae Park, Sung-Sik Han, Seong Hoon Kim, Seung Duk Lee, Tae Hyun Kim, Soon-ae Lee, Sang Myung Woo, Woo Jin Lee, Eun Kyung Hong; Cancer Res Treat. 2018;50(4):1106-1113. Published online November 16, 2017; DOI: https://doi.org/10.4143/crt.2017.320

Abstract PDF PubReader ePub

Purpose
Even though the therapeutic gold standard of hilar cholangiocarcinoma (HCCA) resection is cancer-free resection margin (RM), surgical treatment still remains challenging. This study evaluated the prognostic significance of RM status in resected HCCA patients and identified survival prognostic factors.
Materials and Methods
We reviewed records of 96 HCCA patients who underwent surgery from 2001 to 2012 and analyzed the RM status and prognostic factors that affecting survival.
Results
Negative RM (n=31, 33%) was significantly associated with better survival vs. positive RM (n=65, 67%) (mean survival time [MST], 33 months vs. 21 months; p=0.011). Margins with histological findings of non-dysplastic epithelium, low-grade dysplasia, and carcinoma in situ were not associated with survival differences (MST, 33 months vs. 33 months vs. 30 months; p=0.452), whereas positive margins were associated with poorer survival relative to carcinoma in situ (MST, 30 months vs. 21 months; p=0.050). Among patients with R0 resection, narrow (≤ 5 mm) and wide (> 5 mm) margins were not associated with survival differences (MST, 33 months vs. 30 months; p=0.234). Although positive proximal RM was associated with poorer survival compared to negative RM (MST, 19 vs. 33; p=0.002), no survival difference was observed between positive and negative distal RMs (MST, 30 vs. 33; p=0.628). Proximal RM positivity (hazard ratio [HR], 2.688; p=0.007) and nodal involvement (HR, 3.293; p < 0.001) were independent survival prognostic factors.
Conclusion
A clear RM, especially proximal RM status, was significant prognosticator, and proximal bile duct resection to the greatest technically feasible extent may be necessary, with careful consideration of the potential morbidity and oncologic outcomes after resection. However, an aggressive approach to obtain a negative distal RM might be controversial and should be considered carefully, depending on the patient's status.

Citations

Citations to this article as recorded by

Current advance in comprehensive management of hilar cholangiocarcinoma and navigation in surgery: non-systematic reviews
Man Luo, Jiapeng Yang, Kai Zhang, Ji Sun, Zhiyu Lu, Zhihao Wang, Yaowei Hu, Jianxin Zhai, Peng Xie, Tana Siqin, Mengran Lang, Xuan Meng, Hongguang Wang
International Journal of Surgery.2025; 111(2): 2131. CrossRef
Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study
Changkun Zhang, Xia You, Qin Zhang, Dong Wang
Investigational New Drugs.2024; 42(1): 24. CrossRef
Radiographic features predictive of recurrence and survival after surgical resection of perihilar cholangiocarcinoma
Julaluck Promsorn, Panjaporn Naknan, Aumkhae Sookprasert, Kosin Wirasorn, Jarin Chindaprasirt, Attapol Titapun, Piyapharom Intarawichian, Mukesh Harisinghani
Heliyon.2024; 10(7): e28805. CrossRef
Practice guidelines for managing extrahepatic biliary tract cancers
Hyung Sun Kim, Mee Joo Kang, Jingu Kang, Kyubo Kim, Bohyun Kim, Seong-Hun Kim, Soo Jin Kim, Yong-Il Kim, Joo Young Kim, Jin Sil Kim, Haeryoung Kim, Hyo Jung Kim, Ji Hae Nahm, Won Suk Park, Eunkyu Park, Joo Kyung Park, Jin Myung Park, Byeong Jun Song, Yong
Annals of Hepato-Biliary-Pancreatic Surgery.2024; 28(2): 161. CrossRef
Influence of Perineural (Pn), Lymphangio (L) and Vascular (V) Invasion on Survival after Resection of Perihilar Cholangiocarcinoma
Rabea Margies, Lisa-Katharina Gröger, Beate K. Straub, Fabian Bartsch, Hauke Lang
Cancers.2024; 16(20): 3463. CrossRef
Liver transplantation for unresectable Klatskin tumor: experience of two centers, first distant results
D. A. Granov, V. N. Zhuikov, I. I. Tileubergenov, A. V. Moiseenko, I. O. Rutkin, A. R. Sheraliev, A. A. Polikarpov, O. O. Rummo, A. E. Shcherba, I. P. Shturich, S. V. Korotkov, L. V. Kirkovsky, T. M. Chernishov
Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery.2024; 29(3): 70. CrossRef
Significance of dysplasia in bile duct resection margin in patients with extrahepatic cholangiocarcinoma: A retrospective analysis
Jung Wan Choe, Hyo Jung Kim, Jae Seon Kim
World Journal of Clinical Cases.2022; 10(10): 3078. CrossRef
Klatskin Tumor: A Survival Analysis According to Tumor Characteristics and Inflammatory Ratios
Vlad-Ionuţ Nechita, Emil Moiş, Luminiţa Furcea, Mihaela-Ancuţa Nechita, Florin Graur
Medicina.2022; 58(12): 1788. CrossRef
Impact of Remnant Carcinoma in Situ at the Ductal Stump on Long‐Term Outcomes in Patients with Distal Cholangiocarcinoma
Koya Yasukawa, Akira Shimizu, Hiroaki Motoyama, Koji Kubota, Tsuyoshi Notake, Kentaro Fukushima, Tomohiko Ikehara, Hikaru Hayashi, Akira Kobayashi, Yuji Soejima
World Journal of Surgery.2021; 45(1): 291. CrossRef
Comprehensive analysis of genomic alterations of Chinese hilar cholangiocarcinoma patients
Feiling Feng, Xiaobing Wu, Xiaoliang Shi, Qingxiang Gao, Yue Wu, Yong Yu, Qingbao Cheng, Bin Li, Bin Yi, Chen Liu, Qing Hao, Lin Zhang, Chunfang Gao, Xiaoqing Jiang
International Journal of Clinical Oncology.2021; 26(4): 717. CrossRef
Prognostic Impact of Perioperative CA19-9 Levels in Patients with Resected Perihilar Cholangiocarcinoma
Jong Woo Lee, Jae Hoon Lee, Yejong Park, Jaewoo Kwon, Woohyung Lee, Ki Byung Song, Dae Wook Hwang, Song Cheol Kim
Journal of Clinical Medicine.2021; 10(7): 1345. CrossRef
Prognostic Predictability of American Joint Committee on Cancer 8th Staging System for Perihilar Cholangiocarcinoma: Limited Improvement Compared with the 7th Staging System
Jong Woo Lee, Jae Hoon Lee, Yejong Park, Woohyung Lee, Jaewoo Kwon, Ki Byung Song, Dae Wook Hwang, Song Cheol Kim
Cancer Research and Treatment.2020; 52(3): 886. CrossRef
Comparative study of laparoscopic‐assisted and open total gastrectomy for Siewert Types II and III adenocarcinoma of the esophagogastric junction
Jianchu Wang, Jin‐Cheng Wang, Bin Song, Xu‐Dong Dai, Xiao‐Yu Zhang
Journal of Cellular Physiology.2019; 234(7): 11235. CrossRef
Surgical management of carcinoma in situ at ductal resection margins in patients with extrahepatic cholangiocarcinoma
Toshifumi Wakai, Jun Sakata, Tomohiro Katada, Yuki Hirose, Daiki Soma, Pankaj Prasoon, Kohei Miura, Takashi Kobayashi
Annals of Gastroenterological Surgery.2018; 2(5): 359. CrossRef

8,980 View
246 Download
19 Web of Science
14 Crossref

Inter-alpha Inhibitor H4 as a Potential Biomarker Predicting the Treatment Outcomes in Patients with Hepatocellular Carcinoma: Eun-Jung Lee, Seung-Hyun Yang, Kyoung-Jin Kim, Hyejung Cha, Seo Jin Lee, Ji-Hye Kim, Junkyu Song, Kyung-Hee Chun, Jinsil Seong; Cancer Res Treat. 2018;50(3):646-657. Published online July 17, 2017; DOI: https://doi.org/10.4143/crt.2016.550

Abstract PDF Supplementary Material PubReader ePub

Purpose
Early prediction of treatment outcomes represents an essential step towards increased treatment efficacy and survival in patients with hepatocellular carcinoma (HCC). In this study, we performed two-dimensional electrophoresis (2-DE) followed by protein profiling to identify biomarkers predictive of therapeutic outcomes in patients with HCC who received liver-directed therapy (LDTx) involving local radiotherapy (RT), and studied the underlying mechanisms of the identified proteins.
Materials and Methods
2-DE analysis was conducted by pooling sera from patients with a good or poor prognosis; serum proteomic profiles of the two groups were compared and analyzed using matrixassisted laser desorption/ionization time-of-flight mass spectrometry. Identified proteins were confirmed via enzyme-linked immunosorbent assay. An invasion assay was performed after overexpression and knockdown of target protein in Huh7 cells.
Results
Levels of inter-alpha inhibitor H4 (ITIH4), fibrinogen gamma chain, keratin 9/1 complex, carbonic anhydrase I, and carbonmonoxyhemoglobin S were changed by more than 4-fold in response to LDTx. In particular, pre-LDTx ITIH4 expression was more than 5-fold higher in patients with a good prognosis, compared to patients with a poor prognosis. The migration ability of Huh7 cells was significantly suppressed and enhanced by ITIH4 overexpression and knockdown, respectively. The tumors of patients with HCC and a good prognosis expressed high levels of ITIH4, compared to those of patients with a poor prognosis.
Conclusion
Taken together, ITIH4 may be a potential therapeutic target that could inhibit cancer metastasis, as well as a prognostic marker for patients with HCC who are receiving LDTx.

Citations

Citations to this article as recorded by

Mass spectrometry-based proteomics of cerebrospinal fluid in pediatric central nervous system malignancies: a systematic review with meta-analysis of individual patient data
Christian Mirian, Maria Thastrup, René Mathiasen, Kjeld Schmiegelow, Jesper Velgaard Olsen, Ole Østergaard
Fluids and Barriers of the CNS.2024;[Epub] CrossRef
Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravis
Christina B. Schroeter, Christopher Nelke, Frauke Stascheit, Niklas Huntemann, Corinna Preusse, Vera Dobelmann, Lukas Theissen, Marc Pawlitzki, Saskia Räuber, Alice Willison, Anna Vogelsang, Adela Della Marina, Hans-Peter Hartung, Nico Melzer, Felix F. Ko
Acta Neuropathologica.2024;[Epub] CrossRef
The function of the inter-alpha-trypsin inhibitors in the development of disease
Xin-feng Zhang, Xiao-li Zhang, Li Guo, Yun-ping Bai, Yan Tian, Hua-you Luo
Frontiers in Medicine.2024;[Epub] CrossRef
Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Arising From Intraductal Papillary Mucinous Neoplasms of the Pancreas
William A. Ziaziaris, Christopher S. H. Lim, Loretta Sioson, Anthony J. Gill, Jaswinder S. Samra, Sumit Sahni, Anubhav Mittal
Cancer Medicine.2024;[Epub] CrossRef
Characterization of the Limbal Epithelial Stem Cell Niche
Isabel Y. Moreno, Arian Parsaie, Tarsis F. Gesteira, Vivien J. Coulson-Thomas
Investigative Opthalmology & Visual Science.2023; 64(13): 48. CrossRef
Leveraging Blood-Based Diagnostics to Predict Tumor Biology and Extend the Application and Personalization of Radiotherapy in Liver Cancers
Franziska Hauth, Hannah J. Roberts, Theodore S. Hong, Dan G. Duda
International Journal of Molecular Sciences.2022; 23(4): 1926. CrossRef
Regulatory network identified by pulmonary transcriptome and proteome profiling reveals extensive change of tumor-related genes in microRNA-21 knockout mice
Ge Luan, Ming Wang, Jing Yuan, Xiangting Bu, Jing Song, Chengshuo Wang, Luo Zhang
Journal of Cancer Research and Clinical Oncology.2022; 148(8): 1919. CrossRef
Identification of main influencing factors on the protein corona composition of PLGA and PLA nanoparticles
Hendrik Spreen, Matthias Behrens, Dennis Mulac, Hans-Ulrich Humpf, Klaus Langer
European Journal of Pharmaceutics and Biopharmaceutics.2021; 163: 212. CrossRef
Clinical Assay for the Early Detection of Colorectal Cancer Using Mass Spectrometric Wheat Germ Agglutinin Multiple Reaction Monitoring
I-Jung Tsai, Emily Chia-Yu Su, I-Lin Tsai, Ching-Yu Lin
Cancers.2021; 13(9): 2190. CrossRef
Liver-specific over-expression of Cripto-1 in transgenic mice promotes hepatocyte proliferation and deregulated expression of hepatocarcinogenesis-related genes and signaling pathways
Yu Liu, Yan-Qing Li, Shi-Hao Huang, Yong-Long Li, Jia-Wei Xia, Jun-Shuang Jia, Fang Wei, Jia-Hong Wang, Guan-Qi Dai, Yu-Cai Wang, Xiao-Yan Li, Liu-Xin Han, Xiao-Ling Zhang, Xu-Dong Xiang, Wen-Tao Zhao, Dong Xiao, Xiao-Lin Lin
Aging.2021; 13(17): 21155. CrossRef
ITIH4 is a novel serum biomarker for early gastric cancer diagnosis
Yingying Sun, Jie Jin, Hongyan Jing, Yingying Lu, Qingqing Zhu, Changjuan Shu, Qinghua Zhang, Dadao Jing
Clinica Chimica Acta.2021; 523: 365. CrossRef
The Alterations in Methylene Blue/Light-Treated Frozen Plasma Proteins Revealed by Proteomics
Tiange Wu, Xiaoning Wang, Kai Ren, Xiaochen Huang, Jiankai Liu
Transfusion Medicine and Hemotherapy.2021; 48(5): 298. CrossRef
The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma
Lucas Trevisan França de Lima, Daniel Broszczak, Xi Zhang, Kim Bridle, Darrell Crawford, Chamindie Punyadeera
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2020; 1874(2): 188451. CrossRef
Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data
Lazaro Hiram Betancourt, Krzysztof Pawłowski, Jonatan Eriksson, A. Marcell Szasz, Shamik Mitra, Indira Pla, Charlotte Welinder, Henrik Ekedahl, Per Broberg, Roger Appelqvist, Maria Yakovleva, Yutaka Sugihara, Kenichi Miharada, Christian Ingvar, Lotta Lund
Scientific Reports.2019;[Epub] CrossRef
Plasma Inter-Alpha-Trypsin Inhibitor Heavy Chains H3 and H4 Serve as Novel Diagnostic Biomarkers in Human Colorectal Cancer
Xiao Jiang, Xiao-Yan Bai, Bowen Li, Yanan Li, Kangkai Xia, Miao Wang, Shujing Li, Huijian Wu
Disease Markers.2019; 2019: 1. CrossRef

11,622 View
243 Download
18 Web of Science
15 Crossref

Magnetic Resonance Imaging for Colorectal Cancer Metastasis to the Liver: Comparative Effectiveness Research for the Choice of Contrast Agents: Nieun Seo, Mi-Suk Park, Kyunghwa Han, Kyung Ho Lee, Seong Ho Park, Gi Hong Choi, Jin-Young Choi, Yong Eun Chung, Myeong-Jin Kim; Cancer Res Treat. 2018;50(1):60-70. Published online March 14, 2017; DOI: https://doi.org/10.4143/crt.2016.533

Abstract PDF PubReader ePub

Purpose
This study was conducted to compare the diagnostic performance and early recurrence rate between gadoxetic acid–enhanced magnetic resonance imaging (Gd-EOB-MRI) and magnetic resonance imaging (MRI) with extracellular contrast agent (ECA-MRI) for evaluating hepatic lesions in colorectal cancer.
Materials and Methods
Between 2005 and 2010, 418 colorectal cancer patients with both preoperative computed tomography (CT) and liver MRI were retrospectively reviewed. Image analysis was based on initial radiologic reports, and diagnostic performance was assessed based on the area under the receiver operating characteristic curve (AUROC). The early intrahepatic recurrence rate within 6 months was then evaluated.
Results
Overall, 291 and 127 patients underwent Gd-EOB-MRI and ECA-MRI, respectively. The AUROCs were not significantly different between Gd-EOB-MRI (0.990; 95% CI, 0.980 to 0.999) and ECA-MRI (0.985; 95% CI, 0.968 to 1.000; p=0.836). When compared with CT alone, ECA-MRI detected additional 21 lesions in 14 patients (14/127, 11.0%), whereas Gd-EOB-MRI detected 56 lesions in 33 patients (33/291, 11.3%) without a significant difference between two MRI groups (p=0.331). The early recurrence rate in the ECA-MRI (28.6%) was significantly higher than that in the Gd-EOB-MRI (11.6%) for patients who underwent hepatic resection (p=0.031).
Conclusion
Gd-EOB-MRI is potentially better than ECA-MRI for decreasing the early intrahepatic recurrence rate, although the two MRI modalities showed comparable diagnostic performance in colorectal cancer patients.

Citations

Citations to this article as recorded by

Clinical performance of a simulated abbreviated liver magnetic resonance imaging in combination with contrast-enhanced computed tomography for the baseline evaluation of the liver in patients with colorectal cancer
F. Castagnoli, S.J. Withey, M. Konidari, I. Chau, A. Riddell, J. Shur, C. Messiou, D.M. Koh
Clinical Radiology.2025; 80: 106743. CrossRef
Collaborative multi-feature extraction and scale-aware semantic information mining for medical image segmentation
Ruijun Zhang, Zixuan He, Jian Zhu, Xiaochen Yuan, Guoheng Huang, Chi-Man Pun, Jianhong Peng, Junzhong Lin, Jian Zhou
Physics in Medicine & Biology.2022; 67(20): 205008. CrossRef
Diagnostic Performance of Deep Learning-Based Lesion Detection Algorithm in CT for Detecting Hepatic Metastasis from Colorectal Cancer
Kiwook Kim, Sungwon Kim, Kyunghwa Han, Heejin Bae, Jaeseung Shin, Joon Seok Lim
Korean Journal of Radiology.2021; 22(6): 912. CrossRef
Application of intraoperative ultrasound in liver surgery
Ya-Wei Xu, Hong Fu
Hepatobiliary & Pancreatic Diseases International.2021; 20(5): 501. CrossRef
Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma
Hye Jin Kim, Mi-Suk Park, Jin Yong Lee, Kyunghwa Han, Yong Eun Chung, Jin-Young Choi, Myeong-Jin Kim, Chang Moo Kang
Cancer Research and Treatment.2019; 51(1): 24. CrossRef
Abbreviated Gadoxetic Acid–enhanced MRI with Second-Shot Arterial Phase Imaging for Liver Metastasis Evaluation
Jeong Woo Kim, Chang Hee Lee, Yang Shin Park, Jongmee Lee, Kyeong Ah Kim
Radiology: Imaging Cancer.2019; 1(1): e190006. CrossRef
Intraoperative Ultrasound Staging for Colorectal Liver Metastases in the Era of Liver-Specific Magnetic Resonance Imaging: Is It Still Worthwhile?
Serena Langella, Francesco Ardito, Nadia Russolillo, Elena Panettieri, Serena Perotti, Caterina Mele, Felice Giuliante, Alessandro Ferrero
Journal of Oncology.2019; 2019: 1. CrossRef
Capabilities of ¹⁸F-FDG PET/CT in the differential diagnosis of colorectal liver metastases
M. S. Tlostanova, A. L. Dolbov, A. A. Stanzhevskii
Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery.2019; 24(4): 18. CrossRef
Imagerie par résonance magnétique dans le bilan local préopératoire des cancers du rectum
M. Djelouah, C. Durot, S. Deguelte-Lardière, J. Cohen, A. Devie, L. Protin-Catteau, C. Hoeffel
EMC - Radiologie et imagerie médicale - Abdominale - Digestive.2019; 37(2): 1. CrossRef

12,455 View
357 Download
9 Web of Science
9 Crossref

Blocking Interleukin-4 Receptor α Using Polyethylene Glycol Functionalized Superparamagnetic Iron Oxide Nanocarriers to Inhibit Breast Cancer Cell Proliferation: Abjal Pasha Shaik, Asma Sultana Shaik, Ali Al Majwal, Achraf Al Faraj; Cancer Res Treat. 2017;49(2):322-329. Published online July 12, 2016; DOI: https://doi.org/10.4143/crt.2016.091

Abstract PDF PubReader ePub

Purpose
The specific targeting of interleukin-4 receptor α (IL4Rα) receptor offers a promising therapeutic approach for inhibition of tumor cell progression in breast cancer patients. In the current study, the in vitro efficacy of superparamagnetic iron oxide nanoparticles conjugated with anti-IL4Rα blocking antibodies (SPION-IL4Rα) via polyethylene glycol polymers was evaluated in 4T1 breast cancer cells.
Materials and Methods
Cell viability, reactive oxygen species generation, and apoptosis frequency were assessed in vitro in 4T1 cancer cell lines following exposure to SPION-IL4Rα alone or combined with doxorubicin. In addition, immunofluorescence assessments and fluorimetrywere performed to confirm the specific targeting and interaction of the developed nanocarriers with IL4Rα receptors in breast cancer cells.
Results
Blocking of IL4Rα receptors caused a significant decrease in cell viability and induced apoptosis in 4T1 cells. In addition, combined treatment with SPION-IL4Rα+doxorubicin caused significant increases in cell death, apoptosis, and oxidative stress compared to either SPION-IL4Rα or doxorubicin alone, indicating the enhanced therapeutic efficacy of this combination. The decrease in fluorescence intensity upon immunofluorescence and fluorimetry assays combined with increased viability and decreased apoptosis following the blocking of IL4Rα receptors confirmed the successful binding of the synthesized nanocarriers to the target sites on murine 4T1 breast cancerous cells.
Conclusion
These results suggest that SPION-IL4Rα nanocarriers might be used for successfulreduction of tumor growth and inhibition of progression of metastasis in vivo.

Citations

Citations to this article as recorded by

Nanoscale strides: exploring innovative therapies for breast cancer treatment
Sruthi Laakshmi Mugundhan, Mothilal Mohan
RSC Advances.2024; 14(20): 14017. CrossRef
Innovative Nanoscale Drug Delivery Strategies for Breast Carcinoma: A Comprehensive Exploration
Jaishree S., Kousalya Selvaraj, Prakash S., Vineesh D.
Current Drug Metabolism.2024; 25(6): 391. CrossRef
SPIONs Conjugate Supported Anticancer Drug Doxorubicin’s Delivery: Current Status, Challenges, and Prospects
Naseem Akhtar, Hamdoon A. Mohammed, Mohammed Yusuf, Amal Al-Subaiyel, Ghassan M. Sulaiman, Riaz A. Khan
Nanomaterials.2022; 12(20): 3686. CrossRef
Expression of IL4Rα and IL13Rα1 are associated with poor prognosis of soft-tissue sarcoma of the extremities, superficial trunk, and retroperitoneum
Kyoung Min Kim, Usama Khamis Hussein, See-Hyoung Park, Young Jae Moon, Zhongkai Zhang, Asmaa Gamal Ahmed, Ae-Ri Ahn, Ho Sung Park, Jung Ryul Kim, Kyu Yun Jang
Diagnostic Pathology.2021;[Epub] CrossRef
Magnetic Nanoparticles Used in Oncology
Veronica Manescu (Paltanea), Gheorghe Paltanea, Iulian Antoniac, Marius Vasilescu
Materials.2021; 14(20): 5948. CrossRef
Recent Progress in Iron Oxide Nanoparticles as Therapeutic Magnetic Agents for Cancer Treatment and Tissue Engineering
Mahboubeh Nabavinia, Juan Beltran-Huarac
ACS Applied Bio Materials.2020; 3(12): 8172. CrossRef
Interleukin4Rα (IL4Rα) and IL13Rα1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) Pathways
Mi-Ae Kang, Jongsung Lee, Sang Ha, Chang Lee, Kyoung Kim, Kyu Jang, See-Hyoung Park
Cancers.2019; 11(9): 1394. CrossRef
Targeted Nanoparticle Binding to Hydroxyapatite in a High Serum Environment for Early Detection of Heart Disease
Cari L. Meisel, Polly Bainbridge, Dimitrios Mitsouras, Joyce Y. Wong
ACS Applied Nano Materials.2018; 1(9): 4927. CrossRef
Current aspects in treatment of breast cancer based of nanodrug delivery systems and future prospects
Adil M. Allahverdiyev, Etkin Parlar, Sahar Dinparvar, Melahat Bagirova, Emrah Şefik Abamor
Artificial Cells, Nanomedicine, and Biotechnology.2018; 46(sup3): 755. CrossRef
Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications—Focus on Prostate and Breast Cancer
Jörgen Elgqvist
International Journal of Molecular Sciences.2017; 18(5): 1102. CrossRef

64,905 View
236 Download
10 Web of Science
10 Crossref

Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute: Yooju Shin, Sang Yun Ha, Jiyeon Hyeon, Boram Lee, Jeeyun Lee, Kee-Taek Jang, Kyoung-Mee Kim, Young Suk Park, Cheol-Keun Park; Cancer Res Treat. 2015;47(4):738-746. Published online February 16, 2015; DOI: https://doi.org/10.4143/crt.2014.224

Abstract PDF PubReader ePub

Purpose
Management of gastroenteropancreatic (GEP) neuroendocrine tumors with liver metastases (NETLM) presents many clinical challenges. Assessment of the extent of disease and primary tumor site is crucial for management. In this study, we investigated the primary tumor sites and prognostic factors in GEP NETLM among Korean patients. Materials and Methods We reviewed the medical records of 72 Korean patients diagnosed with GEP NETLM between January 1999 and May 2013, focusing on their clinical and pathologic characteristics.
Results
The most frequently encountered primary tumor sites were the pancreas (n=25, 35%), stomach (n=8, 11%), gall bladder (n=4, 6%) and rectum (n=3, 4%). Twenty-five patients (35%) had occult primary tumor. Twelve patients (17%) had histological grade G1 tumors, 30 patients (42%) had G2 tumors, and 30 patients (42%) had G3 tumors. The mean follow-up period after histological confirmation of hepatic metastases was 11.30±2.44 months for G3 tumors, 19.67±4.09 months for G2 tumors, and 30.67±6.51 months for G1 tumors. Multivariate analyses revealed that an unknown primary tumor site (p=0.001) and higher histological grade (p < 0.001) were independent prognostic indicators for shorter overall survival (OS). Most long-term survivors (OS > 24 months) had received antitumor treatment. Conclusion The primary tumor site most frequently associated with GEP NETLM was the pancreas. Unknown primary tumor and higher histological grade were independent prognostic indicators for shorter OS. Patients identified as being at a risk of shorter OS should be followed up closely.

Citations

Citations to this article as recorded by

The Value of Ultrasound and Contrast‐Enhanced Ultrasound in a Young Asymptomatic Patient With Duodenal Neuroendocrine Neoplasms: A Case Report
Huiyu Yang, Lin Zhao, Xiang Jing, Yanmin Kan
Journal of Clinical Ultrasound.2025;[Epub] CrossRef
Clinicopathological Characteristics of Nonfunctional Pancreatic Neuroendocrine Neoplasms and the Effect of Surgical Treatment on the Prognosis of Patients with Liver Metastases: A Study Based on the SEER Database
Abuduhaibaier Sadula, Gang Li, Dianrong Xiu, Chen Ye, Siqian Ren, Xin Guo, Chunhui Yuan, Min Tang
Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef
Effects of tumor origins and therapeutic options on the prognosis of hepatic neuroendocrine tumors
Xiaoxiao Jiao, Wenqing Luan, Xiaoqian Peng, Lu Liu, Lianfeng Zhang, Lin Zhou
Medicine.2020; 99(51): e23655. CrossRef
Analysis of B-ultrasound and contrast-enhanced ultrasound characteristics of different hepatic neuroendocrine neoplasm
Xiao-Ning Kang, Xiao-Yu Zhang, Jie Bai, Zun-Yi Wang, Wen-Jie Yin, Li Li
World Journal of Gastrointestinal Oncology.2019; 11(5): 436. CrossRef
Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies
Lingaku Lee, Tetsuhide Ito, Robert T Jensen
Expert Review of Anticancer Therapy.2019; 19(12): 1029. CrossRef
A Case Report: Gastric Mixed Neuroendocrine-Nonneuroendocrine Neoplasm with Aggressive Neuroendocrine Component
Quang Duy Pham, Ichiro Mori, Robert Y. Osamura
Case Reports in Pathology.2017; 2017: 1. CrossRef
Pancreatic neuroendocrine tumor Grade 1 patients followed up without surgery: Case series
Mitsuru Sugimoto, Tadayuki Takagi, Rei Suzuki, Naoki Konno, Hiroyuki Asama, Ko Watanabe, Jun Nakamura, Hitomi Kikuchi, Yuichi Waragai, Mika Takasumi, Satoshi Kawana, Yuko Hashimoto, Takuto Hikichi, Hiromasa Ohira
World Journal of Clinical Oncology.2017; 8(3): 293. CrossRef
Gastroenteropancreatic—origin neuroendocrine carcinomas
Yong Gyun Won, Kyung-Jin Seo, Jiyeon Hyeon, Ok Ran Shin, Eundeok Chang, Der Sheng Sun, Hae Sung Won, Yoon Ho Ko, Sae Jung Na, Su Lim Lee, Young Mi Ku, Dong Soo Lee
Medicine.2017; 96(49): e9009. CrossRef
A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases
Liangtao Ye, Huilin Ye, Quanbo Zhou, Zhihua Li, Qing Lin, Langping Tan, Wenchao Gao, Zhiqiang Fu, Shangyou Zheng, Rufu Chen
International Journal of Surgery.2016; 29: 108. CrossRef
Liver Metastasis of Gastrointestinal Neuroendocrine Tumors: A Single Center Experience
Bita Geramizadeh, Ali Kashkooe, Seyed Ali Malekhosseini
Hepatitis Monthly.2016;[Epub] CrossRef
Neuroendocrine neoplasms of liver - A 5-year retrospective clinico-pathological study applying World Health Organization 2010 classification
Deepak Kalyansingh Burad, Thomas Alex Kodiatte, Sayd Mohamed Rajeeb, Ashish Goel, Chundamannil Eapen Eapen, Banumathi Ramakrishna
World Journal of Gastroenterology.2016; 22(40): 8956. CrossRef
Unusual endoscopic findings of gastric neuroendocrine tumor
Kazuhiro Kishi, Akihiko Fujisawa, Minoru Horikita, Yoshihiro Nakai, Kazushi Ooshimo, Fumiko Kishi, Masako Kimura, Chun-che Lin, Tetsuji Takayama
The Journal of Medical Investigation.2015; 62(3.4): 251. CrossRef

12,321 View
78 Download
12 Web of Science
12 Crossref

Novel Methods for Clinical Risk Stratification in Patients with Colorectal Liver Metastases: Ki-Yeol Kim, Nam Kyu Kim, In-Ho Cha, Joong Bae Ahn, Jin Sub Choi, Gi-Hong Choi, Joon Suk Lim, Kang Young Lee, Seung Hyuk Baik, Byung Soh Min, Hyuk Hur, Jae Kyung Roh, Sang Joon Shin; Cancer Res Treat. 2015;47(2):242-250. Published online September 11, 2014; DOI: https://doi.org/10.4143/crt.2014.066

Abstract PDF PubReader ePub

Purpose
Colorectal cancer patients with liver-confined metastases are classified as stage IV, but their prognoses can differ from metastases at other sites. In this study, we suggest a novel method for risk stratification using clinically effective factors. Materials and Methods Data on 566 consecutive patients with colorectal liver metastasis (CLM) between 1989 and 2010 were analyzed. This analysis was based on principal component analysis (PCA). Results The survival rate was affected by carcinoembryonic antigen (CEA) level (p < 0.001; risk ratio, 1.90), distribution of liver metastasis (p=0.014; risk ratio, 1.46), and disease-free interval (DFI; p < 0.001; risk ratio, 1.98). When patients were divided into three groups according to PCA score using significantly affected factors, they showed significantly different survival patterns (p < 0.001). Conclusion The PCA scoring system based on CEA level, distribution of liver metastasis, and DFI may be useful for preoperatively determining prognoses in order to assist in clinical decisionmaking and designing future clinical trials for CLM treatment.

Citations

Citations to this article as recorded by

Differential Perspectives by Specialty on Oligometastatic Colorectal Cancer: A Korean Oligometastasis Working Group’s Comparative Survey Study
Won Kyung Cho, Gyu Sang Yoo, Chai Hong Rim, Jae-Uk Jeong, Eui Kyu Chie, Yong Chan Ahn, Hyeon-Min Cho, Jun Won Um, Yang-Gun Suh, Ah Ram Chang, Jong Hoon Lee
Cancer Research and Treatment.2023; 55(4): 1281. CrossRef
Long disease-free interval diminishes the prognostic value of primary tumor stage for patients with colorectal cancer liver metastases
Jia-Ming Liu, Yan-Yan Wang, Wei Liu, Da Xu, Kun Wang, Bao-Cai Xing
HPB.2022; 24(5): 737. CrossRef
A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases
You Jin Chun, Seong-Geun Kim, Keun-Wook Lee, Sang Hee Cho, Tae Won Kim, Ji Yeon Baek, Young Suk Park, Soojung Hong, Chong Woo Chu, Seung-Hoon Beom, Minkyu Jung, Sang Joon Shin, Joong Bae Ahn
Clinical Colorectal Cancer.2020; 19(3): e140. CrossRef
Preclinical Efficacy of [V4 Q5 ]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer
Juan Garona, Natasha T. Sobol, Marina Pifano, Valeria I. Segatori, Daniel E. Gomez, Giselle V. Ripoll, Daniel F. Alonso
Cancer Research and Treatment.2019; 51(2): 438. CrossRef
A multi-gene expression profile panel for predicting liver metastasis: An algorithmic approach
Kanisha Shah, Shanaya Patel, Sheefa Mirza, Rakesh M. Rawal, Kapil Mehta
PLOS ONE.2018; 13(11): e0206400. CrossRef
A combined prognostic factor for improved risk stratification of patients with oral cancer
K‐Y Kim, X Zhang, S‐M Kim, B‐D Lee, I‐H Cha
Oral Diseases.2017; 23(1): 91. CrossRef

11,540 View
87 Download
7 Web of Science
6 Crossref

Preclinical Efficacy Testing for Stomach and Liver Cancers: Jun Won Park, Nam Suk Baek, Seok Cheol Lee, Su Jin Oh, Seok Hoon Jang, In Hoo Kim, Dae Yong Kim, Hark Kyun Kim; Cancer Res Treat. 2014;46(2):186-193. Published online April 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.2.186

Abstract PDF PubReader ePub

Purpose

Hollow fiber assays offer an early in vivo method of anticancer drug screening. The assays have been optimized for human cancers originating from the lung, breast, colon, ovary, and brain, but not from the stomach and liver. The current study focused on optimization of hollow fiber assays for gastric and hepatocellular carcinoma cell lines.

Materials and Methods

Gastric (SNU-16, SNU-484, SNU-668) and hepatocellular (HepG2, SK-Hep-1, Hep3B) carcinoma cell lines in hollow fibers were transplanted subcutaneously and intraperitoneally into mice, which were subsequently treated with a standard anticancer agent, paclitaxel. The hollow fiber activity of paclitaxel in each cell line was compared with the xenograft activity.

Results

Using optimized inoculation densities and schedules, treatment with paclitaxel was effective in gastric carcinoma cell lines, SNU-16 and SNU-484, but not in SNU-668. In the hollow fiber assays, paclitaxel was effective in hepatocellular carcinoma cell lines, HepG2 and SK-Hep-1, but not in Hep3B. Consistent with the results of the hollow fiber assay, SNU-16 and SNU-484, but not SNU-668, showed tumor regression, and HepG2 and SK-Hep-1, but not Hep3B, showed effective tumor responses following treatment with paclitaxel in xenograft models. When EW7197, a novel compound, and flavopiridol were tested in SNU-16 cells under optimized conditions, the hollow fiber activity showed good correlation with the xenograft activity of each compound.

Conclusion

Our protocols may be useful for screening candidate small molecules that may exhibit activity against stomach and liver cancers, both of which are common in Korea.

Citations

Citations to this article as recorded by

Synopsis on the Linkage of Alzheimer's and Parkinson's Disease with Chronic Diseases
Nasimudeen R. Jabir, Chelapram K. Firoz, Saleh S. Baeesa, Ghulam Md Ashraf, Suhail Akhtar, Warda Kamal, Mohammad A. Kamal, Shams Tabrez
CNS Neuroscience & Therapeutics.2015; 21(1): 1. CrossRef
The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression
Jeong Min Kim, Hei-Cheul Jeung, Sun Young Rha, Eun Jeong Yu, Tae Soo Kim, You Keun Shin, Xianglan Zhang, Kyu Hyun Park, Seung Woo Park, Hyun Cheol Chung, Garth Powis
Molecular Cancer Therapeutics.2014; 13(12): 3074. CrossRef

12,664 View
132 Download
3 Web of Science
2 Crossref

Case Report

Primary Follicular Lymphoma in a Male Breast: A Case Report: Seung Pil Jung, Kang Min Han, Seok Jin Kim, Seok Jin Nam, Jeoung Won Bae, Jeong Eon Lee; Cancer Res Treat. 2014;46(1):104-107. Published online January 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.1.104

Abstract PDF PubReader ePub

Primary breast lymphoma (PBL) is a rare disease, particularly in males. Diffuse large B cell lymphoma is the most common PBL, while follicular lymphoma is less common. Furthermore, primary follicular lymphoma of a male breast is rarely reported. We report a male patient with primary follicular lymphoma of the breast and hepatocellular carcinoma (HCC). A 46-year-old man was diagnosed with liver cirrhosis secondary to chronic hepatitis B infection. Ten years later, he underwent segmentectomy of the liver due to HCC. Another 5 months later, he presented with a painless mass in the right chest wall. The mass was diagnosed as follicular lymphoma of the breast. The stage was IEA and he did not receive adjuvant therapy. Although only a few cases have been reported, lymphoma should be considered as a possible cause of breast mass, even in male patients.

Citations

Citations to this article as recorded by

Clinicopathologic and mutational profiles of primary breast diffuse large B cell lymphoma in a male patient: case report and literature review
Fengbo Huang, Yachao Ruan, Xiaojuan He, Hui Lian, Jinhua Yang
World Journal of Surgical Oncology.2023;[Epub] CrossRef
Primary breast lymphoma in males: Incidence, demographics, prognostic factors, survival, and comparisons with females
Jie Zhang, Binbin Ma, Hong Ji, Rong Guo
Frontiers in Surgery.2022;[Epub] CrossRef
Hematologic Malignancies of the Breast: A Contemporary Series Investigating Incidence, Presentation, Accuracy of Diagnosis on Core Needle Biopsy, and Hormone Receptor Expression
Marie-Christine Guilbert, Jason L Hornick, Sona A Chikarmane, Susan C Lester
Breast Cancer: Basic and Clinical Research.2019;[Epub] CrossRef
Case - lymphoma of breast
Eva Němcová, Andrea Janíková, Jiřina Little, Eva Jandáková, Hana Čučková, Karel Dvořák
Česká radiologie.2015; 69(3): 207. CrossRef

15,777 View
66 Download
5 Web of Science
4 Crossref

Review Article

Advances of Cancer Therapy by Nanotechnology: Xu Wang, Yiqing Wang, Zhuo Georgia Chen, Dong M. Shin; Cancer Res Treat. 2009;41(1):1-11. Published online March 31, 2009; DOI: https://doi.org/10.4143/crt.2009.41.1.1

Abstract PDF PubReader ePub

Recent developments in nanotechnology offer researchers opportunities to significantly transform cancer therapeutics. This technology has enabled the manipulation of the biological and physicochemical properties of nanomaterials to facilitate more efficient drug targeting and delivery. Clinical investigations suggest that therapeutic nanoparticles can enhance efficacy and reduced side effects compared with conventional cancer therapeutic drugs. Encouraged by rapid and promising progress in cancer nanotechnology, researchers continue to develop novel and efficacious nanoparticles for drug delivery. The use of therapeutic nanoparticles as unique drug delivery systems will be a significant addition to current cancer therapeutics.

Citations

Citations to this article as recorded by

Bridging the nano-Frontier: revolutionizing lung cancer diagnosis and therapy with nanoparticles
Joysa Ruby Joseph, Pavithra S, K. Selvakumar, Venkatesh DP
International Journal of Polymeric Materials and Polymeric Biomaterials.2025; 74(7): 595. CrossRef
Aloe vera gel mediated green synthesis of ruthenium nanoparticles and their potential anticancer activity
Tanjila Begum, Sangeeta Agarwal, Pranjal Bhuyan, Jumi Das, Akalesh Kumar Verma, Ankur Guha, Mausumi Ganguly
Next Nanotechnology.2025; 7: 100095. CrossRef
Next-Gen Cancer Treatment: Nanotechnology-Driven siRNA Delivery Solutions
Harshita, Vancha Harish, Sakshi Lad Upendra, Sharfuddin Mohd, Sachin Kumar Singh, Pooja Agrawal, Sukriti Vishwas, Kamal Dua
ASSAY and Drug Development Technologies.2025;[Epub] CrossRef
Nano Nutraceuticals: Revolutionizing the Future of Health Supplements
Firoj Allauddin Tamboli, Rupali Sugram Waghmare, Sharayu Rajkumar Gajewar, Divya Ganesh Gavhane, Pratik Pandurang Disale, Priyanka Ramesh Jogi, Ujwala Suryakant Mali
Biomedical and Pharmacology Journal.2025; 18(1): 459. CrossRef
Nanoparticles of banana peels as a potential source of bioactive compounds and their activities on HepG2
Donia S. Hassanin, Sahar R. Abdelhady, Adel Kh. Ghazi, Waleed Z. Badawy
Scientific Reports.2025;[Epub] CrossRef
Extracellular vesicles and exosome-like nanovesicles as pioneering oral drug delivery systems
Jagannath Mondal, Shameer Pillarisetti, Vijayabhaskarreddy Junnuthula, Sachin S. Surwase, Seung Rim Hwang, In-Kyu Park, Yong-kyu Lee
Frontiers in Bioengineering and Biotechnology.2024;[Epub] CrossRef
Recent Trends in Nanocarrier-Based Drug Delivery System for Prostate Cancer
Amit Kumar, Akshay Kumar Lunawat, Ashutosh Kumar, Tarun Sharma, Md Moidul Islam, Milan Singh Kahlon, Debanjan Mukherjee, Raj Kumar Narang, Sarjana Raikwar
AAPS PharmSciTech.2024;[Epub] CrossRef
Advancements in Nutraceutical Delivery: Integrating Nanotechnology and Microencapsulation for Enhanced Efficacy and Bioavailability
Shanzay Gul, Tahseen Fatima Miano, Anees Mujeeb, Muzafaruddin Chachar, Memoona Islam Majeedano, Ghazal Murtaza, Wazeer Ahmed, Yasha Abid Khanzada, Mariam Ansari
Matrix Science Pharma.2024; 8(1): 1. CrossRef
Capparis zeylanica-mediated Ag/ZnO nanoparticles and their antiproliferative efficacy via nuclear apoptosis
P. Suresh, A. Doss, G. Rajeswari, T. P. Kumari Pushpa Rani, R. P. Praveen Pole, S. Satheesh
Advances in Traditional Medicine.2024; 24(3): 935. CrossRef
Research progress of copper-based metal–organic frameworks for cancer diagnosis and therapy
Xian Li, Zhifang Ma, Haozheng Wang, Qiang Shi, Zhigang Xie, Jinhai Yu
Coordination Chemistry Reviews.2024; 514: 215943. CrossRef
Advances in inorganic nanoparticles-based drug delivery in targeted breast cancer theranostics
Vahid Rahimkhoei, Asaad H. Alzaidy, May Jaleel Abed, Somaye Rashki, Masoud Salavati-Niasari
Advances in Colloid and Interface Science.2024; 329: 103204. CrossRef
Nanohybrid cerasomes: Advancements in targeted drug and gene delivery
Kalyani Pathak, Mohammad Zaki Ahmad, Riya Saikia, Partha Protim Borthakur, Pallab Pramanik, Md Ariful Islam, Aparoop Das, Basel A. Abdel-Wahab, Dibyajyoti Das, Saptasikha Gogoi
European Journal of Medicinal Chemistry Reports.2024; 12: 100178. CrossRef
Receptor-Targeted Nanomedicine for Cancer Therapy
Arvee Prajapati, Shagun Rangra, Rashmi Patil, Nimeet Desai, Vaskuri G. S. Sainaga Jyothi, Sagar Salave, Prakash Amate, Derajram Benival, Nagavendra Kommineni
Receptors.2024; 3(3): 323. CrossRef
BODIPY‐based iridium and ruthenium complexes: Synthesis, photophysical, and photochemical properties
Beyza Cabir, Seda Cetindere
Journal of the Chinese Chemical Society.2024; 71(11): 1402. CrossRef
Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics
Uttpal Anand, Abhijit Dey, Arvind K. Singh Chandel, Rupa Sanyal, Amarnath Mishra, Devendra Kumar Pandey, Valentina De Falco, Arun Upadhyay, Ramesh Kandimalla, Anupama Chaudhary, Jaspreet Kaur Dhanjal, Saikat Dewanjee, Jayalakshmi Vallamkondu, José M. Pére
Genes & Diseases.2023; 10(4): 1367. CrossRef
Ursolic acid: a pentacyclic triterpenoid that exhibits anticancer therapeutic potential by modulating multiple oncogenic targets
Sardul Singh Sandhu, Sharareh Khorami Rouz, Suneel Kumar, Nitin Swamy, Loknath Deshmukh, Arif Hussain, Shafiul Haque, Hardeep Singh Tuli
Biotechnology and Genetic Engineering Reviews.2023; 39(2): 729. CrossRef
Novel thiosemicarbazone and thiazolidin‐4‐one derivatives containing vanillin core: Synthesis, characterization, and anticancer activity studies
Feyzi Sinan Tokalı, Halil Şenol, Tuğba Gençoğlu Katmerlikaya, Aydan Dağ, Kıvılcım Şendil
Journal of Heterocyclic Chemistry.2023; 60(4): 645. CrossRef
The Effects of Curcumin on Inflammasome: Latest Update
Tarek Benameur, Socorro Vanesca Frota Gaban, Giulia Giacomucci, Francesca Martina Filannino, Teresa Trotta, Rita Polito, Giovanni Messina, Chiara Porro, Maria Antonietta Panaro
Molecules.2023; 28(2): 742. CrossRef
Approved Nanomedicine against Diseases
Yuanchao Jia, Yuxin Jiang, Yonglong He, Wanting Zhang, Jiahui Zou, Kosheli Thapa Magar, Hamza Boucetta, Chao Teng, Wei He
Pharmaceutics.2023; 15(3): 774. CrossRef
Preparation, Characterization and Evaluation of a Novel Drug Carrier for the Controlled Release of Curcumin
Faseela Kasim, Archana Somasekharan Nair, Aswathy Lalitha Balachandran, Moorikoval Parambil Sooraj, Anoop Somasekharan Nair
Drug Research.2023; 73(04): 224. CrossRef
Functionalization of curcumin nanomedicines: a recent promising adaptation to maximize pharmacokinetic profile, specific cell internalization and anticancer efficacy against breast cancer
Jinku Zhang, Jirui Sun, Chong Li, Haizhi Qiao, Zahid Hussain
Journal of Nanobiotechnology.2023;[Epub] CrossRef
Advanced Delivery System of Polyphenols for Effective Cancer Prevention and Therapy
Koung Hee Kim, Mi-Ran Ki, Ki Ha Min, Seung Pil Pack
Antioxidants.2023; 12(5): 1048. CrossRef
Fabrication and characterization of bee venom-loaded nanoliposomes: Enhanced anticancer activity against different human cancer cell lines via the modulation of apoptosis-related genes
Alaa Abd El-Gawad, Mohamed A. Kenawy, Tamer M. El-Messery, Marwa E. Hassan, Aziza A. El-Nekeety, Mosaad A. Abdel-Wahhab
Journal of Drug Delivery Science and Technology.2023; 84: 104545. CrossRef
Development and Statistical Optimization of Polymer-Based Nanoparticulate Delivery System for Enhancing Cytarabine Efficacy in Leukemia Treatment
Nasrullah Jan, Asadullah Madni, Hassan Shah, Safiullah Khan, Qazi Amir Ijaz, Syed Faisal Badshah, Ahsan Ali, Umair Khurshid, Mohammad F. Bostanudin
Journal of Pharmaceutical Innovation.2023; 18(4): 1713. CrossRef
Hybrid Nanoplatforms Comprising Organic Nanocompartments Encapsulating Inorganic Nanoparticles for Enhanced Drug Delivery and Bioimaging Applications
Fatih Yanar, Dario Carugo, Xunli Zhang
Molecules.2023; 28(15): 5694. CrossRef
Current status of Fe-based MOFs in biomedical applications
Hanping Yang, Donghui Liao, Zhidong Cai, Yuelin Zhang, Alireza Nezamzadeh-Ejhieh, Mingbin Zheng, Jianqiang Liu, Zhi Bai, Hailiang Song
RSC Medicinal Chemistry.2023; 14(12): 2473. CrossRef
Molecular Mechanism of Inhibition of Glioma by Targeting Autophagy Microtubule-Associated Protein 1A/1B-Light Chain 3 Family via miR-16 with Novel Liposome Nanoparticles
Chunyang Xing, Weiping Cai, Yiru Fang, Qikun Wang, Yan Huang, Yuzhe Wang, Weiwei Wang
Journal of Biomedical Nanotechnology.2023; 19(11): 1891. CrossRef
A Comprehensive Review on Targeted Cancer Therapy: New Face of Treatment Approach
Dipanjan Karati, Dileep Kumar
Current Pharmaceutical Design.2023; 29(41): 3282. CrossRef
Extension in the approaches to treat cancer through siRNA system: a beacon of hope in cancer therapy
Indra Rautela, Aditi Sharma, Pallavi Dheer, Priya Thapliyal, Shweta Sahni, Vimlendu Bhushan Sinha, Manish Dev Sharma
Drug Delivery and Translational Research.2022; 12(5): 1002. CrossRef
Development and Characterization of 5-Fluorouracil Solid Lipid Nanoparticles for Treatment of Colorectal Cancer
Poournima Patil, Suresh Killedar, Harinath More, Ganesh Vambhurkar
Journal of Pharmaceutical Innovation.2022; 17(4): 1268. CrossRef
Synthesis of oleanolic acid hydrazide-hydrazone hybrid derivatives and investigation of their cytotoxic effects on A549 human lung cancer cells
Şenol Halil, Mercümek Berre, Şahin Rabia Büşra, Kapucu Halil Burak, Hacıosmanoğlu Ebru
Results in Chemistry.2022; 4: 100317. CrossRef
Therapeutic Nanoparticles: Advantages and Toxicity
Dr. Lata Ramrakhiani
Indian Journal of Environment Engineering.2022; 2(1): 19. CrossRef
Green-synthesized gold nanoparticles from black tea extract enhance the chemosensitivity of doxorubicin in HCT116 cells via a ROS-dependent pathway
Tanushree Das, Snehasis Mishra, Sayoni Nag, Krishna Das Saha
RSC Advances.2022; 12(15): 8996. CrossRef
Promising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials
Natalia Krasteva, Milena Georgieva
Pharmaceutics.2022; 14(6): 1213. CrossRef
Polymer-Based Materials and their Applications in Image-Guided Cancer Therapy
Yang Sun, Haitao Ran, Fan Liu
Current Medicinal Chemistry.2022; 29(8): 1352. CrossRef
Polymeric nanoparticles-siRNA as an emerging nano-polyplexes against ovarian cancer
Urushi Rehman, Neha Parveen, Afsana Sheikh, Mohammed A.S. Abourehab, Amirhossein Sahebkar, Prashant Kesharwani
Colloids and Surfaces B: Biointerfaces.2022; 218: 112766. CrossRef
Wnt/β-catenin targeting in liver carcinoma through nanotechnology-based drug repurposing: A review
Priyadarshini Mohapatra, Natarajan Chandrasekaran
Biomedicine & Pharmacotherapy.2022; 155: 113713. CrossRef
Immunocyte‐Derived Nanodrugs for Cancer Therapy
Xiao‐Yu Zhu, Tian‐Yu Wang, Hao‐Ran Jia, Fu‐Gen Wu
Advanced Functional Materials.2022;[Epub] CrossRef
Nanocarriers and their Types for Targeted Drug Delivery
Nazma. Shaik, Prasanth. Y
International Journal of Pharmaceutical Sciences Review and Research.2022; : 21. CrossRef
Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives
Zehra Edis, Junli Wang, Muhammad Khurram Waqas, Muhammad Ijaz, Munazza Ijaz
International Journal of Nanomedicine.2021; Volume 16: 1313. CrossRef
Novel Green Biosynthesis of 5-Fluorouracil Chromium Nanoparticles Using Harpullia pendula Extract for Treatment of Colorectal Cancer
Mohammed S. Saddik, Mahmoud M. A. Elsayed, Mohamed Salaheldin A. Abdelkader, Mohamed A. El-Mokhtar, Jelan A. Abdel-Aleem, Ahmed M. Abu-Dief, Mostafa F. Al-Hakkani, Hatem S. Farghaly, Heba A. Abou-Taleb
Pharmaceutics.2021; 13(2): 226. CrossRef
Nanomaterials-Mediated Immunomodulation for Cancer Therapeutics
Ajita Jindal, Sounik Sarkar, Aftab Alam
Frontiers in Chemistry.2021;[Epub] CrossRef
Fabrication of Versatile Hollow Metal–Organic Framework Nanoplatforms for Folate-Targeted and Combined Cancer Imaging and Therapy
Xiaoli Zeng, Bin Chen, Yibo Song, Xiaofeng Lin, Shu-Feng Zhou, Guowu Zhan
ACS Applied Bio Materials.2021; 4(8): 6417. CrossRef
Urokinase Plasminogen Activator Receptor-Mediated Targeting of a Stable Nanocomplex Coupled with Specific Peptides for Imaging of Cancer
Deepshikha Shahdeo, Akshay B. Chandra, Sonu Gandhi
Analytical Chemistry.2021; 93(34): 11868. CrossRef
Carbon Dots: An Innovative Tool for Drug Delivery in Brain Tumors
Giovanna Calabrese, Giovanna De Luca, Giuseppe Nocito, Maria Giovanna Rizzo, Sofia Paola Lombardo, Giulia Chisari, Stefano Forte, Emanuele Luigi Sciuto, Sabrina Conoci
International Journal of Molecular Sciences.2021; 22(21): 11783. CrossRef
Basics to advances in nanotherapy of colorectal cancer
Ankita Tiwari, Shivani Saraf, Ankit Jain, Pritish K. Panda, Amit Verma, Sanjay K. Jain
Drug Delivery and Translational Research.2020; 10(2): 319. CrossRef
Molecular Insights into the Loading and Dynamics of Doxorubicin on PEGylated Graphene Oxide Nanocarriers
Mina Mahdavi, Ali Fattahi, Emad Tajkhorshid, Sasan Nouranian
ACS Applied Bio Materials.2020; 3(3): 1354. CrossRef
Preparation and characterization of stable fluorescent As4S4/ZnS/Fe3O4 nanosuspension capped by Poloxamer 407 and folic acid
Z. Lukáčová Bujňáková, O. Shpotyuk, I. Syvorotka, P. Demchenko, E. Dutková, E. Tóthová, Z. Bártová
Applied Nanoscience.2020; 10(12): 4651. CrossRef
“Watson–Crick GC”-inspired supramolecular nanodrug of methotrexate and 5-fluorouracil for tumor microenvironment-activatable self-recognizing synergistic chemotherapy
Meijin Chen, Shiduan Chen, Fukai Zhu, Fanfan Wang, Haina Tian, Zhongxiong Fan, Sunkui Ke, Zhenqing Hou, Yang Li
Journal of Materials Chemistry B.2020; 8(17): 3829. CrossRef
The Emerging Role of Curcumin in the Modulation of TLR-4 Signaling Pathway: Focus on Neuroprotective and Anti-Rheumatic Properties
Maria Antonietta Panaro, Addolorata Corrado, Tarek Benameur, Cantatore Francesco Paolo, Daniela Cici, Chiara Porro
International Journal of Molecular Sciences.2020; 21(7): 2299. CrossRef
CRGDK-Functionalized PAMAM-Based Drug-Delivery System with High Permeability
Dongfang Liu, Chao Wang, Jian Yang, Yanli An, Rui Yang, Gaojun Teng
ACS Omega.2020; 5(16): 9316. CrossRef
Nanomaterials as potential transporters of HDAC inhibitors
Cristabelle De Souza, Zhao Ma, Aaron Raymond Lindstrom, Biswa Prasun Chatterji
Medicine in Drug Discovery.2020; 6: 100040. CrossRef
Natural ligand-receptor mediated loading of siRNA in milk derived exosomes
Shruti Shandilya, Payal Rani, Suneel Kumar Onteru, Dheer Singh
Journal of Biotechnology.2020; 318: 1. CrossRef
Inhibition of Glioma Cells’ Proliferation by Doxorubicin-Loaded Exosomes via Microfluidics

Abhimanyu Thakur, Rakesh Kumar Sidu, Heng Zou, Md Kowsar Alam, Mengsu Yang, Youngjin Lee
International Journal of Nanomedicine.2020; Volume 15: 8331. CrossRef
Synthesis, In Silico Prediction and In Vitro Evaluation of Antitumor Activities of Novel Pyrido[2,3-d]pyrimidine, Xanthine and Lumazine Derivatives
Samar El-Kalyoubi, Fatimah Agili
Molecules.2020; 25(21): 5205. CrossRef
Development of nanoparticulate systems with action in breast and ovarian cancer: nanotheragnostics
Fabiana de Sousa Cunha, Laise Nayra dos Santos Pereira, Thâmara Pryscilla de Costa e Silva, Roberto Alves de Sousa Luz, Anderson Nogueira Mendes
Journal of Drug Targeting.2019; 27(7): 732. CrossRef
Nanocarriers for drug delivery applications
Munusamy Chamundeeswari, John Jeslin, Madan Lal Verma
Environmental Chemistry Letters.2019; 17(2): 849. CrossRef
Folic-Acid-Adorned PEGylated Graphene Oxide Interferes with the Cell Migration of Triple Negative Breast Cancer Cell Line, MDAMB-231 by Targeting miR-21/PTEN Axis through NFκB
Arijita Basu, Priyanka Upadhyay, Avijit Ghosh, Dipankar Chattopadhyay, Arghya Adhikary
ACS Biomaterials Science & Engineering.2019; 5(1): 373. CrossRef
Innovative nano-carriers in anticancer drug delivery-a comprehensive review
Peng Dong, K.P. Rakesh, H.M. Manukumar, Yasser Hussein Eissa Mohammed, C.S. Karthik, S. Sumathi, P. Mallu, Hua-Li Qin
Bioorganic Chemistry.2019; 85: 325. CrossRef
Liposomal Taro Lectin Nanocapsules Control Human Glioblastoma and Mammary Adenocarcinoma Cell Proliferation
Anna C. N. T. F. Corrêa, Mauricio A. Vericimo, Andriy Dashevskiy, Patricia R. Pereira, Vania M. F. Paschoalin
Molecules.2019; 24(3): 471. CrossRef
Modulation of Biological Activities in Glioblastoma Mediated by Curcumin
Teresa Trotta, Maria A. Panaro, Elona Prifti, Chiara Porro
Nutrition and Cancer.2019; 71(8): 1241. CrossRef
Laponite-based Nanomaterials for Biomedical Applications: A Review
Sabya S. Das, Neelam, Kashif Hussain, Sima Singh, Afzal Hussain, Abdul Faruk, Mike Tebyetekerwa
Current Pharmaceutical Design.2019; 25(4): 424. CrossRef
Efficient nanocarriers of siRNA therapeutics for cancer treatment
Md Abdus Subhan, V.P. Torchilin
Translational Research.2019; 214: 62. CrossRef
Hydrophobically modified inulin-based micelles: Transport mechanisms and drug delivery applications for breast cancer
Siddharth S. Kesharwani, Rakesh Dachineni, G. Jayarama Bhat, Hemachand Tummala
Journal of Drug Delivery Science and Technology.2019; 54: 101254. CrossRef
Perspectives of Molecularly Imprinted Polymer-Based Drug Delivery Systems in Cancer Therapy
Andreea Elena Bodoki, Bogdan-Cezar Iacob, Ede Bodoki
Polymers.2019; 11(12): 2085. CrossRef
Nanomaterials as nanocarriers: a critical assessment why these are multi-chore vanquisher in breast cancer treatment
Sania Naz, Hira Shahzad, Attarad Ali, Muhammad Zia
Artificial Cells, Nanomedicine, and Biotechnology.2018; 46(5): 899. CrossRef
Antimicrobial peptides, nanotechnology, and natural metabolites as novel approaches for cancer treatment
Michel L. Leite, Nicolau B. da Cunha, Fabricio F. Costa
Pharmacology & Therapeutics.2018; 183: 160. CrossRef
A novel self-assembled nanoparticle platform based on pectin-eight-arm polyethylene glycol-drug conjugates for co-delivery of anticancer drugs
Yanxue Liu, Kefeng Liu, Xiaomin Li, Shangzhen Xiao, Dan Zheng, Pengbo Zhu, Chunxiao Li, Jing Liu, Jing He, Jiandu Lei, Luying Wang
Materials Science and Engineering: C.2018; 86: 28. CrossRef
Synthesis, Optical, and Structural Studies of Iron Sulphide Nanoparticles and Iron Sulphide Hydroxyethyl Cellulose Nanocomposites from Bis-(Dithiocarbamato)Iron(II) Single-Source Precursors
Athandwe Paca, Peter Ajibade
Nanomaterials.2018; 8(4): 187. CrossRef
Protein adsorption and macrophage uptake of zwitterionic sulfobetaine containing micelles
Aijing Lu, Zhengzhong Wu, Xianglin Luo, Suming Li
Colloids and Surfaces B: Biointerfaces.2018; 167: 252. CrossRef
Self-Assembled Nanoparticles Platform Based on Pectin-Dihydroartemisinin Conjugates for Codelivery of Anticancer Drugs
Yanxue Liu, Dan Zheng, Yunyun Ma, Juan Dai, Chunxiao Li, Shangzhen Xiao, Kefeng Liu, Jing Liu, Luying Wang, Jiandu Lei, Jing He
ACS Biomaterials Science & Engineering.2018;[Epub] CrossRef
Evaluation of chromosomal aberrations induced by 188Re-dendrimer nanosystem on B16f1 melanoma cells
Marcos Tassano, Natalia Oddone, Marcelo Fernández, Williams Porcal, María Fernanda García, Wilner Martínez-López, Juan Claudio Benech, Pablo Cabral
International Journal of Radiation Biology.2018; 94(7): 664. CrossRef
A highly integrated precision nanomedicine strategy to target esophageal squamous cell cancer molecularly and physically
Xin-shuai Wang, Xue-zhen Ding, Xiao-cen Li, Yixuan He, De-jiu Kong, Li Zhang, Xiao-chen Hu, Jun-qiang Yang, Meng-qi Zhao, She-gan Gao, Tzu-yin Lin, Yuanpei Li
Nanomedicine: Nanotechnology, Biology and Medicine.2018; 14(7): 2103. CrossRef
Electroneutral polymersomes for combined cancer chemotherapy
Noorjahan Aibani, Heather Nesbitt, Nino Marino, Joanna Jurek, Caolin O'Neill, Chloe Martin, Ivana Di Bari, Yingjie Sheng, Kieran Logan, Susan Hawthorne, Anthony McHale, John F. Callan, Bridgeen Callan
Acta Biomaterialia.2018; 80: 327. CrossRef
A novel honokiol liposome: formulation, pharmacokinetics, and antitumor studies
Chuchu Zhou, Chenqi Guo, Wenhao Li, Juan Zhao, Qin Yang, Tiantian Tan, Zhuoya Wan, Jianxia Dong, Xu Song, Tao Gong
Drug Development and Industrial Pharmacy.2018; 44(12): 2005. CrossRef
Multifunctional nanoparticle developments in cancer diagnosis and treatment
Sepideh Parvanian, Seyed Mojtaba Mostafavi, Meysam Aghashiri
Sensing and Bio-Sensing Research.2017; 13: 81. CrossRef
Carbon nanotubes: a novel material for multifaceted applications in human healthcare
Sandeep Kumar, Ruma Rani, Neeraj Dilbaghi, K. Tankeshwar, Ki-Hyun Kim
Chemical Society Reviews.2017; 46(1): 158. CrossRef
Targeting nanocarriers containing antisense oligonucleotides to cancer cell
Parth Patel, Y.K. Agrawal
Journal of Drug Delivery Science and Technology.2017; 37: 97. CrossRef
Targeted si-RNA with liposomes and exosomes (extracellular vesicles): How to unlock the potential
Sophia Antimisiaris, Spyridon Mourtas, Konstantina Papadia
International Journal of Pharmaceutics.2017; 525(2): 293. CrossRef
Down–regulation of cyclin–dependent kinase-4 and MAPK through estrogen receptor mediated cell cycle arrest in human breast cancer induced by gold nanoparticle tagged toxin protein NKCT1
Tanmoy Bhowmik, Antony Gomes
Chemico-Biological Interactions.2017; 268: 119. CrossRef
Targeted Magnetic Nanotheranostics of Cancer
Irina Belyanina, Olga Kolovskaya, Sergey Zamay, Ana Gargaun, Tatiana Zamay, Anna Kichkailo
Molecules.2017; 22(6): 975. CrossRef
Targeted delivery of bromelain using dual mode nanoparticles: synthesis, physicochemical characterization, in vitro and in vivo evaluation
Rozita Nasiri, Javad Hamzehalipour Almaki, Ani Idris, Mahtab Nasiri, Muhammad Irfan, Fadzilah Adibah Abdul Majid, Hamid Rashidi Nodeh, Rosnani Hasham
RSC Advances.2017; 7(64): 40074. CrossRef
Self-Assembled Pectin-Conjugated Eight-Arm Polyethylene Glycol–Dihydroartemisinin Nanoparticles for Anticancer Combination Therapy
Yanxue Liu, Qi Qi, Xiaomin Li, Jing Liu, Luying Wang, Jing He, Jiandu Lei
ACS Sustainable Chemistry & Engineering.2017; 5(9): 8097. CrossRef
Ursolic acid nanoparticles inhibit cervical cancer growth in vitro and in vivo via apoptosis induction
Shaoguang Wang, Xiaomei Meng, Yaozhong Dong
International Journal of Oncology.2017; 50(4): 1330. CrossRef
Preparation, Characterization, and Preliminary In Vitro Testing of Nanoceria-Loaded Liposomes
Agostina Grillone, Tianshu Li, Matteo Battaglini, Alice Scarpellini, Mirko Prato, Shinji Takeoka, Gianni Ciofani
Nanomaterials.2017; 7(9): 276. CrossRef
Small Interfering RNA in Milk Exosomes Is Resistant to Digestion and Crosses the Intestinal Barrier In Vitro
Shruti Shandilya, Payal Rani, Suneel Kumar Onteru, Dheer Singh
Journal of Agricultural and Food Chemistry.2017; 65(43): 9506. CrossRef
Exosomes for the Enhanced Tissue Bioavailability and Efficacy of Curcumin
Farrukh Aqil, Radha Munagala, Jeyaprakash Jeyabalan, Ashish Kumar Agrawal, Ramesh Gupta
The AAPS Journal.2017; 19(6): 1691. CrossRef
Fabrication of doxorubicin nanoparticles by controlled antisolvent precipitation for enhanced intracellular delivery
Yu Tong Tam, Kenneth Kin Wah To, Albert Hee Lum Chow
Colloids and Surfaces B: Biointerfaces.2016; 139: 249. CrossRef
Advances in silica based nanoparticles for targeted cancer therapy
Yannan Yang, Chengzhong Yu
Nanomedicine: Nanotechnology, Biology and Medicine.2016; 12(2): 317. CrossRef
Supramolecular assembly of a succinyl-calix[4]arene derivative in multilamellar vesicles
Giuseppe Granata, Grazia M. L. Consoli, Raffaella Lo Nigro, Graziella Malandrino, Corrada Geraci
Supramolecular Chemistry.2016; 28(5-6): 377. CrossRef
Etirinotecan pegol for the treatment of breast cancer
Elena López-Miranda, Javier Cortés
Expert Opinion on Pharmacotherapy.2016; 17(5): 727. CrossRef
Study of anti-cancer properties of green silver nanoparticles against MCF-7 breast cancer cell lines
Shweta Rajawat, Rajnish Kurchania, Katherukamen Rajukumar, Shreyas Pitale, Sonali Saha, M.S. Qureshi
Green Processing and Synthesis.2016;[Epub] CrossRef
Upconversion nanoparticles for tumor imaging with near-infrared radiation
V. V. Rocheva, D. A. Khochenkov, A. N. Generalova, A. V. Nechaev, V. A. Semchishen, E. V. Stepanova, V. I. Sokolov, E. V. Khaydukov, V. Ya. Panchenko
Bulletin of the Russian Academy of Sciences: Physics.2016; 80(4): 467. CrossRef
Conjugation of Docetaxel with Multiwalled Carbon Nanotubes and Codelivery with Piperine: Implications on Pharmacokinetic Profile and Anticancer Activity
Kaisar Raza, Dinesh Kumar, Chanchal Kiran, Manish Kumar, Santosh Kumar Guru, Pramod Kumar, Shweta Arora, Gajanand Sharma, Shashi Bhushan, O. P. Katare
Molecular Pharmaceutics.2016; 13(7): 2423. CrossRef
Development of hematin conjugated PLGA nanoparticle for selective cancer targeting
Md. Lutful Amin, Dami Kim, SeJin Kim
European Journal of Pharmaceutical Sciences.2016; 91: 138. CrossRef
Biosynthesized Vitis vinifera seed gold nanoparticles induce apoptotic cell death in A431 skin cancer cells
J. Grace Nirmala, S. Akila, M. S. A. Muthukumar Nadar, R. T. Narendhirakannan, Suvro Chatterjee
RSC Advances.2016; 6(85): 82205. CrossRef
Biodegradable polymeric nanoparticles containing gold nanoparticles and Paclitaxel for cancer imaging and drug delivery using photoacoustic methods
Yanjie Wang, Eric M. Strohm, Yang Sun, Zhaoxia Wang, Yuanyi Zheng, Zhigang Wang, Michael C. Kolios
Biomedical Optics Express.2016; 7(10): 4125. CrossRef
Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives
Amit Alexander, Ajazuddin, Ravish J. Patel, Swarnlata Saraf, Shailendra Saraf
Journal of Controlled Release.2016; 241: 110. CrossRef
Cancer active targeting by nanoparticles: a comprehensive review of literature
Remon Bazak, Mohamad Houri, Samar El Achy, Serag Kamel, Tamer Refaat
Journal of Cancer Research and Clinical Oncology.2015; 141(5): 769. CrossRef
Synthesis, characterization, and pharmacological evaluation of some novel thiadiazoles and thiazoles incorporating pyrazole moiety as anticancer agents
Sobhi M. Gomha, Taher A. Salah, Abdou O. Abdelhamid
Monatshefte für Chemie - Chemical Monthly.2015; 146(1): 149. CrossRef
Delivery systems for siRNA drug development in cancer therapy
Cong-fei Xu, Jun Wang
Asian Journal of Pharmaceutical Sciences.2015; 10(1): 1. CrossRef
Advances in Combination Therapies Based on Nanoparticles for Efficacious Cancer Treatment: An Analytical Report
Serge Mignani, Maria Bryszewska, Barbara Klajnert-Maculewicz, Maria Zablocka, Jean-Pierre Majoral
Biomacromolecules.2015; 16(1): 1. CrossRef
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Edgar Pérez-Herrero, Alberto Fernández-Medarde
European Journal of Pharmaceutics and Biopharmaceutics.2015; 93: 52. CrossRef
Carbon nanotubes: Properties, biomedical applications, advantages and risks in patients and occupationally-exposed workers
M Lamberti, P Pedata, N Sannolo, S Porto, A De Rosa, M Caraglia
International Journal of Immunopathology and Pharmacology.2015; 28(1): 4. CrossRef
Novel biodegradable heparin-coated nanocomposite system for targeted drug delivery
Amaneh Javid, Shahin Ahmadian, Ali Akbar Saboury, Seyed Mehdi Kalantar, Saeed Rezaei-Zarchi
RSC Adv..2014; 4(26): 13719. CrossRef
Intracellular transport of nanodiamond particles in human endothelial and epithelial cells
Katarzyna Solarska-Ściuk, Agnieszka Gajewska, Sława Glińska, Maciej Studzian, Sylwia Michlewska, Łucja Balcerzak, Janusz Skolimowski, Bogumiła Kolago, Grzegorz Bartosz
Chemico-Biological Interactions.2014; 219: 90. CrossRef
Preclinical development of siRNA therapeutics: Towards the match between fundamental science and engineered systems
M. Videira, A. Arranja, D. Rafael, R. Gaspar
Nanomedicine: Nanotechnology, Biology and Medicine.2014; 10(4): 689. CrossRef
Effect of functionalized and non-functionalized nanodiamond on the morphology and activities of antioxidant enzymes of lung epithelial cells (A549)
Katarzyna Solarska-Ściuk, Agnieszka Gajewska, Sława Glińska, Sylwia Michlewska, Łucja Balcerzak, Agnieszka Jamrozik, Janusz Skolimowski, Květoslava Burda, Grzegorz Bartosz
Chemico-Biological Interactions.2014; 222: 135. CrossRef
Preparation of 5-fluorouracil-loaded Nanoparticles and Study of Interaction with Gastric Cancer Cells
Yu-Ling Fan, Bing-Yu Fan, Qiang Li, Hai-Xiao Di, Xiang-Yu Meng, Na Ling
Asian Pacific Journal of Cancer Prevention.2014; 15(18): 7611. CrossRef
Passive targeting of nanoparticles to cancer: A comprehensive review of the literature
REMON BAZAK, MOHAMAD HOURI, SAMAR EL ACHY, WAEL HUSSEIN, TAMER REFAAT
Molecular and Clinical Oncology.2014; 2(6): 904. CrossRef
Antileukemic potential of PEGylated gold nanoparticle conjugated with protein toxin (NKCT1) isolated from Indian cobra (Naja kaouthia) venom
Tanmoy Bhowmik, Partha Pratim Saha, Anjan Dasgupta, Antony Gomes
Cancer Nanotechnology.2013; 4(1-3): 39. CrossRef
pH-sensitive Liposomes for Drug Delivery in Cancer Treatment
Diego dos Santos Ferreira, Sávia Caldeira de Araújo Lopes, Marina Santiago Franco, Mônica Cristina Oliveira
Therapeutic Delivery.2013; 4(9): 1099. CrossRef
The inclusion complex of 4-hydroxynonenal with a polymeric derivative of β-cyclodextrin enhances the antitumoral efficacy of the aldehyde in several tumor cell lines and in a three-dimensional human melanoma model
Stefania Pizzimenti, Eric Ciamporcero, Piergiorgio Pettazzoni, Simona Osella-Abate, Mauro Novelli, Cristina Toaldo, Miriam Husse, Martina Daga, Rosalba Minelli, Agnese Bisazza, Paolo Ferruti, Elisabetta Ranucci, Maria Grazia Bernengo, Chiara Dianzani, Fio
Free Radical Biology and Medicine.2013; 65: 765. CrossRef
Highly efficient double-stranded RNA transfection of penaeid shrimp using cationic liposomes
Nuttapon Apiratikul, Boon-ek Yingyongnarongkul, Wanchai Assavalapsakul
Aquaculture Research.2013; 45(1): 106. CrossRef
Preparation, Physicochemical Characterization, and Cell Viability Evaluation of Long-Circulating and pH-Sensitive Liposomes Containing Ursolic Acid
Sávia Caldeira de Araújo Lopes, Marcus Vinícius Melo Novais, Cláudia Salviano Teixeira, Kinulpe Honorato-Sampaio, Márcio Tadeu Pereira, Lucas Antônio Miranda Ferreira, Fernão Castro Braga, Mônica Cristina Oliveira
BioMed Research International.2013; 2013: 1. CrossRef
Carbon nanotubes as a novel drug delivery system for anticancer therapy: a review
Swatantra Kumar Singh Kushwaha, Saurav Ghoshal, Awani Kumar Rai, Satyawan Singh
Brazilian Journal of Pharmaceutical Sciences.2013; 49(4): 629. CrossRef
A Novel 5-Fluorouracil-Loaded Polyelectrolyte Nanoparticle Formulation
Yu Ling Fan, Bing Yu Fan, Qiang Li, Shuang Leng, Li Hua Ma
Advanced Materials Research.2013; 690-693: 518. CrossRef
Poly(ethylene carbonate) Nanoparticles as Carrier System for Chemotherapy Showing Prolonged in vivo Circulation and Anti‐Tumor Efficacy
Thomas Renette, Damiano Librizzi, Thomas Endres, Olivia Merkel, Moritz Beck‐Broichsitter, Nadja Bege, Holger Petersen, Catherine Curdy, Thomas Kissel
Macromolecular Bioscience.2012; 12(7): 970. CrossRef
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
Susana Patricia Egusquiaguirre, Manuela Igartua, Rosa María Hernández, José Luis Pedraz
Clinical and Translational Oncology.2012; 14(2): 83. CrossRef
The anticancer activity of chloroquine-gold nanoparticles against MCF-7 breast cancer cells
Prachi Joshi, Soumyananda Chakraborti, Jaime E. Ramirez-Vick, Z.A. Ansari, Virendra Shanker, Pinak Chakrabarti, Surinder P. Singh
Colloids and Surfaces B: Biointerfaces.2012; 95: 195. CrossRef
Submicron-size biodegradable polymer-based didanosine particles for treating HIV at early stage: anin vitrostudy
Gurudutta Pattnaik, Biswadip Sinha, Biswajit Mukherjee, Saikat Ghosh, Sandip Basak, Subhasish Mondal, Tanmoy Bera
Journal of Microencapsulation.2012; 29(7): 666. CrossRef
Polypeptide-based vesicles: formation, properties and application for drug delivery
Bin Tian, Xiaoguang Tao, Tianyang Ren, Yan Weng, Xia Lin, Yu Zhang, Xing Tang
Journal of Materials Chemistry.2012; 22(34): 17404. CrossRef
Modeling and Improvement of Breast Cancer Site Temperature Profile by Implantation of Onion-Like Quantum-Dot Quantum-Well Heteronanocrystal in Tumor Site
A. SalmanOgli, A. Rostami
IEEE Transactions on Nanotechnology.2012; 11(6): 1183. CrossRef
Aptamer-labeled PLGA nanoparticles for targeting cancer cells
Athulya Aravind, Saino Hanna Varghese, Srivani Veeranarayanan, Anila Mathew, Yutaka Nagaoka, Seiki Iwai, Takahiro Fukuda, Takashi Hasumura, Yasuhiko Yoshida, Toru Maekawa, D. Sakthi Kumar
Cancer Nanotechnology.2012; 3(1-6): 1. CrossRef
Sustained targeting of Bcr–Abl + leukemia cells by synergistic action of dual drug loaded nanoparticles and its implication for leukemia therapy
Sarbari Acharya, Sanjeeb K. Sahoo
Biomaterials.2011; 32(24): 5643. CrossRef
Theranostic Applications of Nanomaterials in Cancer: Drug Delivery, Image-Guided Therapy, and Multifunctional Platforms
Alicia Fernandez-Fernandez, Romila Manchanda, Anthony J. McGoron
Applied Biochemistry and Biotechnology.2011; 165(7-8): 1628. CrossRef
Liposome based delivery systems in pancreatic cancer treatment: From bench to bedside
Feng Yang, Chen Jin, Yongjian Jiang, Ji Li, Yang Di, Quanxing Ni, Deliang Fu
Cancer Treatment Reviews.2011; 37(8): 633. CrossRef
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
Sarbari Acharya, Sanjeeb K. Sahoo
Advanced Drug Delivery Reviews.2011; 63(3): 170. CrossRef
Nanomaterials: Applications in Cancer Imaging and Therapy
José A. Barreto, William O’Malley, Manja Kubeil, Bim Graham, Holger Stephan, Leone Spiccia
Advanced Materials.2011;[Epub] CrossRef
Informatics and standards for nanomedicine technology
Dennis G. Thomas, Fred Klaessig, Stacey L. Harper, Martin Fritts, Mark D. Hoover, Sharon Gaheen, Todd H. Stokes, Rebecca Reznik‐Zellen, Elaine T. Freund, Juli D. Klemm, David S. Paik, Nathan A. Baker
WIREs Nanomedicine and Nanobiotechnology.2011; 3(5): 511. CrossRef
Targeted photodynamic therapy — a promising strategy of tumor treatment
Andrzej M. Bugaj
Photochemical & Photobiological Sciences.2011; 10(7): 1097. CrossRef
Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice
Ahmed M. Al-Abd, Ki-Yun Hong, Soo-Chang Song, Hyo-Jeong Kuh
Journal of Controlled Release.2010; 142(1): 101. CrossRef
Fullerene–Porphyrin Nanostructures in Photodynamic Therapy
Carolina Constantin, Monica Neagu, Rodica-Mariana Ion, Mihaela Gherghiceanu, Crina Stavaru
Nanomedicine.2010; 5(2): 307. CrossRef
The Rise and Rise of Stealth Nanocarriers for Cancer Therapy: Passive Versus Active Targeting
Ngoc Trinh Huynh, Emilie Roger, Nolwenn Lautram, Jean-Pierre Benoît, Catherine Passirani
Nanomedicine.2010; 5(9): 1415. CrossRef

21,000 View
192 Download
134 Crossref

Case Report

Long-term Survival after Surgical Resection for Liver Metastasis from Gastric Cancer: Two Case Reports: Jong Keun Lim, Joong Bae Ahn, Sung Ha Cheon, Hyun Chang, Jong Yul Jung, Sun Young Rha, Jae Kyung Roh, Sung Hoon Noh, Ho Geun Kim, Hyun Cheol Chung, Hei-Cheul Jeung; Cancer Res Treat. 2006;38(3):184-188. Published online June 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.3.184

Abstract PDF PubReader ePub

Surgical resection of colorectal cancer metastasis to the liver results in a 5-year survival rate of around 40%. Liver metastasis from other cancers such as neuroendocrine carcinoma and genitourinary tumors are also treated effectively with combined liver resection. However, hepatic metastasectomy for liver tumor from gastric cancer hasn't been considered as a standard treatment, and the benefit for this treatment has not been established. We report here on two cases of gastrectomy and combined liver resection for synchronous liver metastasis without any evidence of other metastatic lesions, and these two patients have survived for more than 7 years without evidence of disease recurrence. In conclusion, for patients with hepatic metastasis from gastric cancer, combined surgical resection of the liver metastasis should be considered as a treatment option when metastasis to other sites can be excluded.

Citations

Citations to this article as recorded by

Radical gastrectomy with hepatoarterial catheter implantation for late-stage gastric cancer
Guo-Liang Yao
World Journal of Gastroenterology.2015; 21(9): 2754. CrossRef

9,297 View
73 Download
1 Crossref

Original Articles

Identification of Genes Involved in Liver Cancer Cell Growth Using an Antisense Library of Phage Genomic DNA: Yun Han Lee, Young Ho Kim, Jong Gu Park; Cancer Res Treat. 2004;36(4):246-254. Published online August 31, 2004; DOI: https://doi.org/10.4143/crt.2004.36.4.246

Abstract PDF PubReader ePub: Purpose
Genes involved in liver cancer cell growth have been identified using an antisense library of large circular (LC-) genomic DNA of a recombinant M13 phage.
Materials and Methods
A subtracted cDNA library was constructed by combining procedures of suppression subtractive hybridization (SSH) and unidirectional cloning of the subtracted cDNA into an M13 phagemid vector. Utilizing the life cycle of M13 bacteriophages, LC-antisense molecules derived from 1,200 random cDNA clones selected by size were prepared from the culture supernatant of bacterial transformants. The antisense molecules were arrayed for transfection on 96-well plates preseeded with HepG2.
Results
When examined for growth inhibition after antisense transfection, 153 out of 1,200 LC-antisense molecules showed varying degrees of growth inhibitory effect to HepG2 cells. Sequence comparison of the 153 clones identified 58 unique genes. The observations were further extended by other cell-based assays.
Conclusion
These results suggest that the LC-antisense library offers potential for unique high-throughput screening to find genes involved in a specific biological function, and may prove to be an effective target validation system for gene-based drug discovery.

8,250 View
58 Download

Geographical Variation of Liver Cancer Mortality in Korea (1992-1998): Duk Hee Lee, Jin Ha Kim, Byung Hun Han, Sang Ook Lee, Hai Rim Shin, In Chul Jung; Cancer Res Treat. 2001;33(5):420-426. Published online October 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.5.420

Abstract PDF

PURPOSE
The death rate of liver cancer in Korea has been reported as one of the highest in the world. This study was conducted to investigate geographical variations of liver cancer mortality in Korea in order to obtain insight into possible environmental factors related to liver cancer.
MATERIALS AND METHODS
The sex-specific standardized mortality ratios (SMRs) of liver cancer were calculated for 168 basic administrative units in Korea based upon the vital statistics for the seven years 1992 to 1998, as well as the sex- and age-specific population of each area for 1995. The SMRs were classified into six categories and depicted on a map for each sex.
RESULTS
The southern provinces showed clearly higher mortality rates as compared to the rest of the country in both males and females. Looking at the maps in detail, there was a geographical variation even within the southern provinces. The areas around large rivers, some costal areas, and costal islands showed a high mortality rate. Even in the middle and northern provinces, the eastern costal areas showed relatively higher mortality rates as compared to inland areas. Conversely, some southern areas known for low levels of pollution showed relatively lower mortality rates.
CONCLUSION
This finding suggests a possible relationship between liver cancer and water-related foods from polluted rivers or seas. Further studies should be performed in order to clarify which factors cause this geographical variation.

Citations

Citations to this article as recorded by

Regional Factors Affecting Liver Cancer Mortality Using GWR
Jin Hyun Son, Wooseok Ryu
Journal of Health Informatics and Statistics.2024; 49(4): 404. CrossRef
Prevalence and Related Factors of Clonorchiasis among Five Major Riverside Residents in South Korea
Chunmi Kim, Kyung Ja June, Shin Hyeong Cho, Kyung Soon Park, Hung Sa Lee, Ji Yeon Park
Journal of Korean Academy of Community Health Nursing.2016; 27(4): 346. CrossRef
The knowledge and attitudes towards hepatitis B among paramedic students
Bo-Ram Choi, Dong-Ok Kim, Gyung-Hun Min
The Korean Journal of Emergency Medical Services.2016; 20(3): 57. CrossRef
Viral Hepatitis and Liver Cancer in Korea: an Epidemiological Perspective
Yohwan Yeo, Jin Gwack, Seokin Kang, Boyeon Koo, Sun Jae Jung, Prakash Dhamala, Kwang-Pil Ko, Young-Khi Lim, Keun-Young Yoo
Asian Pacific Journal of Cancer Prevention.2013; 14(11): 6227. CrossRef
A Study on the Prevalence of Clonorchis Sinensis and the Effects of Educational Program among Residents in the Basin of the Youngsan River, Korea
Chunmi Kim, Aeyoung So, Kyung-Ja June, Hee Young Jung
Journal of Korean Academy of Community Health Nursing.2011; 22(1): 56. CrossRef
Hepatitis B and C virus prevalence in a rural area of South Korea: the role of acupuncture
H R Shin, J Y Kim, J I Kim, D H Lee, K Y Yoo, D S Lee, S Franceschi
British Journal of Cancer.2002; 87(3): 314. CrossRef

4,330 View
28 Download
6 Crossref

Dose-Response Relationship of Radiotherapy for Locally Advanced Hepatocellular Carcinoma: Dae Yong Kim, Joon Hyoek Lee, Kwang Cheol Koh, Seung Woon Paik, Yong Chan Ahn, Seung Jae Huh, Inhwan J Yeo, Suk Won Park, Seung Hee Chang; J Korean Cancer Assoc. 2000;32(5):918-924.

Abstract PDF: PURPOSE
Recently radiotherapy is applied alone or in conjunction with transcatheter arterial chemoembolizaion (TACE) or percutaneous ethanol injection therapy (PEIT) for locally advanced hepatocellular carcinoma (HCC). The purpose of this study was to evaluate dose-response relationship of radiotherapy for local control and toxicity in inoperable HCC.
MATERIALS AND METHODS
Twenty-eight patients who were not eligible for TACE and PEIT or had showed no response to these treatment were treated with a total dose of 40 Gy with 2 Gy per fraction or 30 Gy with 3 Gy per fraction (low dose group, 18 patients) or 45 Gy with 3 Gy per fraction (high dose group, 10 patients).
RESULTS
The median survival duration was 8 months and 1-year survival rate was 37%. The treatment results were as follows; partial response in 11% and 70% (p=0.001), stable disease in 56% and 30%, and progressive disease in 33% and 0% in low dose group and high dose group, respectively. The incidence of gastrointestinal (G-I) toxicity by the criteria of Southwest Oncology Group was as follows; grade 1 in 22% and 40%, grade 2 in 17% and 10%, respectively (p=0.56). There was no patient with severe G-I toxicity above grade 3. The incidence of G-I toxicity by site was as follows; grade 1 in 24% and 29%, and grade 2 in 0% and 57% in patients with right lobe and left lobe lesion, respectively (p=0.001).
CONCLUSION
This study indicates that there is clear dose-response relationship in local control. The G-I toxicity does not increase significantly with increment of radiation dose within the dose range tested in this study. And careful attention should be paid for G-I toxicity when the tumor is located in left lobe.

2,890 View
15 Download

Radioresponse of Hepatdegrees Celluar Carcinoma Treatment of Lymph Node Metastasis: Jong Hoon Kim, Eun Kyung Choi, Young Wha Chung, Young Sang Lee, Dong Jin Seo; J Korean Cancer Assoc. 2000;32(3):571-577.

Abstract PDF: No abstract available.

2,618 View
19 Download

Risk Factors of Early Recurrenec after Curative Hepatic Resection for Hepatocellular Carcinoma: Jae Hun Choi, Helen Rho, Young Taeg Koh, Kyung Suk Suh, Kuhn Uk Lee; J Korean Cancer Assoc. 1999;31(1):165-172.

Abstract PDF: PURPOSE
The purpose of this study was to clarify the risk factors of early recurrence within 1 year by comparing them with patients without recurrence within 3 years after curative liver resection in hepatocellular carcinoma (HCC).
MATERIALS AND METHODS
Three hundred and twenty six patients with HCC who underwent curative liver resection between 1991 Jan, to 1995 June were observed for possible recurrence for least 3 years. These patients were divided into two groups: 79 patients who had recurrence within 1 years (early recurred group) and 132 patients who had no recurrence within 3 years (no recurred group).
RESULTS
Overall survival rates in 5 years after 1iver resection were 17.5% in early recurred group and 94.9% in no recuned group. Risk factors of early recurrence in multivariate analysis were the presence of liver cirrhosis in nontumorous parenchyme (p=0.011, relative risk (RR)=2.5), tumor size (p=0.004, RR 2.9), multiple mass (p 0.015, RR=3.4), the presence of angioinvasion (p=0.043, RR=3.7), serum alpha-fetoprotein more than 20 ng/dl (p=0.007, RR=2.7), major liver resection more than lobectomy (p=0.039, RR=3.2). However, other factors such as age, sex, preoperative transcatheter arterial embolization (TAE), several liver function tests, Child classification, reseetion margin, total necrosis of tumor after preoperative TAE, tumor encapsulation, histologic type, Edmondsons grade, were not significant in our study.
CONCLUSION
The risk factors of early recurrence were liver cirrhosis, tumor size, number of tumor, angioinvasion, serum alpha-fetoprotein, and major liver resection. Biologic characteristics of tumor were the most important risk factors of early recurrence. Because the extent of liver resection is the only risk factor that depends on surgeons decision, we must consider this factor in liver resection for HCC.

2,746 View
16 Download

Synchronous Expression of Circulating Intercellular Adhesion Molecule-1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1) During Gastric Cancer Progression: Hei Cheol Chung, Joon Oh Park, Sun Young Rha, Hyun Cheol Chung, Soo Jung Gong, Choong Bae Kim, Joo Hang Kim, Jae Kyung Roh, Jin Sik Min, Byung Soo Kim, Sung Hoon Noh; J Korean Cancer Assoc. 1997;29(1):81-92.

Abstract PDF: PURPOSE
The circulating forms of ICAM-1 (cICAM-1) and VCAM-1 (cVCAM-1) has been reported from supernatant of cytokine activated endothelial cells, cancer cells and from cancer patient serum even though the biological significance of the cCAMs are not fully elucidated.
MATERIALS AND METHODS
To evaluate the correlation of the expression of cICAM-1 and cVCAM-1 and prognosis in gastric cancer, we measured cICAM-1 and cVCAM-1 levels in 20 healthy volunteers and 142 gastric cancer patients' sera by ELISA assay. Also we compared cCAMs levels with vascular endothelial growth factor (sVEGF) and FP. Ninety-five patients were operable and 47 patients were advanced or relapsed state at the time of the study. In 28 operable patients, we simultaneously sampled portal and peripheral vein and measured the cCAMs.
RESULTS
The cCAMs level and positive rate in serum increased with cancer progression from healthy control, operable to advanced or relapsed gastric cancer. In advanced cancer, cICAM-1 level increased with liver metastasis. The cICAM-1 level in portal blood was correlated modestly with that in peripheral blood. And in cVCAM-1 positive subgroup, cCAM-1 level correlated with cVCAM-1 level. The peripheral cICAM-1 level decreased in 6% compared to that of portal cICAM-1 level while peripheral cVCAM-1 level increased in 1% compared to that of portal level. Synchronous expression of both cCAMs was found in 58.3% of the patients with liver metastasis and 22.9% of the patients without liver metastasis (p=0.03). But, there were no correlation between cCAMs and FP expression regardless of liver metastasis. The sVEGF level correlated with neither cICAM-1 nor cVCAM-1 level regardless of liver metastasis. The median disease-free and overall survival of patients with synchronous cICAM-1 and cVCAM-1 expression was 8 months and 9 months, while in patients without co-expression it was more than 24 months and 23 months respectively.
CONCLUSION
We suggest that synchronous cICAM-1 and cVCAM-1 elevation may be a useful monitor of tumor burden and progression in gastric cancer, especially in liver metastasis.

2,762 View
19 Download

First
Prev
Page of 2
Next
Last

Search